Abstract
Bound by lineage-determining transcription factors and signaling effectors, enhancers play essential roles in controlling spatiotemporal gene expression profiles during development, homeostasis and disease. Recent synergistic advances in functional genomic technologies, combined with the developmental biology toolbox, have resulted in unprecedented genome-wide annotation of heart enhancers and their target genes. Starting with early studies of vertebrate heart enhancers and ending with state-of-the-art genome-wide enhancer discovery and testing, we will review how studying heart enhancers in metazoan species has helped inform our understanding of cardiac development and disease.
Introduction
The heart is a vital organ whose primary role is to pump blood through the circulatory system to reach different organs. Heart-like structures are ancient and observed across diverse metazoans, including arthropods (such as Drosophila), mollusks (such as octopus) and chordates. Heart structures vary widely across metazoans ranging from a single-layered tubular heart in arthropods and tunicates (including Ciona), three separate hearts in some cephalopods (including octopus), a two-chambered heart in jawed fish, a three-chambered heart in amphibians, to a four-chambered heart in other tetrapods (reviewed in Stephenson et al., 2017; Poelmann and Gittenberger-de Groot, 2019). This lineage-specific tuning of cardiac structures is accompanied by changes in the whole circulatory system and highly adapted to the specific physiological needs of different animals. Despite these differences in heart structure, which are mostly related to later-stage heart morphogenesis, many cellular events and molecular regulators involved in early heart development are broadly shared across metazoan species.
A core set of cardiac transcription factors (TFs), including NK2 (Drosophila homolog: Tinman), MEF2 (Drosophila homolog: Mef2), GATA (Drosophila homolog: Pannier), TBX (Drosophila homolog: Nmr1/2, Doc1/2/3, etc.), and HAND (Drosophila homolog: Hand) families, interact with enhancers to control cardiac gene expression and cell fates in Drosophila, fish, and tetrapods (reviewed in Olson, 2006; Tolkin and Christiaen, 2012; Waardenberg et al., 2014). Though specific usage of paralogs and dosage sensitivities may vary between different species, these core TFs form the “cardiac regulatory kernel” (Tolkin and Christiaen, 2012; Waardenberg et al., 2014) in metazoans by closely interacting with each other and extracellular signaling cues. The requirement of extracellular signaling pathways in cardiogenesis also shows a high degree of conservation. The core signaling pathways, such as WNT, FGF, NOTCH, and BMP, play essential cardiogenic roles in both Drosophila and vertebrates (reviewed in Noseda et al., 2011).
Early vertebrate heart development involves a conserved sequence of cellular events that are seen in most, if not all, classes of vertebrate species (reviewed in Miquerol and Kelly, 2013). These events include: the emergence of specified cardiac progenitors within the anterior lateral plate mesoderm; migration of the cardiac progenitors to the midline to form the linear heart tube; rightward looping and elongation of the primitive heart tube; ballooning of the atrial and ventricular chambers out from the looped tube; and cardiac cushion and valve formation at the atrioventricular canal and outflow tract. This conserved set of events involve the complex interplay of multiple cardiac cell types, including the first heart field progenitors (FHF) that give rise to the linear heart tube and second heart field progenitors (SHF) that provide later addition to both poles of the heart tube (Kelly, 2012). Although cardiomyocytes make up a significant portion of mature hearts, other cell types, such as endocardial cells, smooth muscle cells, and cardiac fibroblasts, are also involved in cardiac development and physiological function (Hu et al., 2018; Honkoop et al., 2019; Tucker et al., 2020).
Understanding the interplay between multiple cardiac TFs and signaling pathways, within and between the cell types involved in cardiogenesis, requires a detailed knowledge of the cis-regulatory elements (CREs) that comprise heart enhancers. The regulatory logic encoded within CREs is readily understood by the embryo and is sufficient to organize multiple cardiac TFs and signaling pathways that ultimately result in a fully formed and functioning heart. In contrast, it has taken decades of experimental advances and insights to develop systems and technologies where cardiac CREs can be discovered and tested.
In this review, we discuss the genetic control of heart development and disease from an enhancer-centric perspective. From early gene-centric enhancer dissection in the 1990s to genome-wide characterization of heart enhancers in development and disease today, the discovery of heart enhancers has substantially shaped our understanding of the principles in cardiac gene regulation. We begin with a brief overview of developmental enhancers followed by a discussion of regulatory principles gained from pre-genomics enhancer studies. We then discuss how rapid advances in genome-wide approaches have transformed our knowledge regarding the locations, interactions, temporal dynamics and functions of heart enhancers. Our review will incorporate evolutionary characteristics of heart enhancers and discuss how new methods for dissecting heart enhancer functions promises to improve our understanding of heart development and cardiovascular diseases.
Enhancer Structure and Function in Development: A Primer
Enhancers are traditionally defined as short non-coding DNA sequences with the ability to drive gene expression regardless of the genomic distance, position, and orientation relative to the cognate genes [i.e., () recently reviewed by ]. Enhancers can influence gene expression over short (hundreds of base pairs, bp) or large (megabases) genomic distances. These distal enhancers form long-range chromatin interactions with their target genes, such as the well-studied ZRS enhancer that is 1 Mb away from its target Shh (Lettice et al., 2003). This flexibility allows a single gene to be regulated by multiple enhancers with different spatiotemporal activities, as well as a single enhancer to contribute to the regulation of multiple genes, which was shown in recent genome-wide enhancer interaction maps (Montefiori et al., 2018; Jung et al., 2019). Together this many-to-many relationship sets up a complex regulatory network to achieve the highly diverse tissue-specific expression patterns evident in development.
Spatial-temporal developmental gene expression is achieved through the combinatorial recruitment of a discrete set of TFs to enhancers (for a recent review of how TFs recognize CREs see Zeitlinger, 2020). TFs interact with enhancers through short degenerate DNA sequence motifs. Recent work investigating the regulatory logic of a typical developmental enhancer supports an overarching principle that specific developmental gene expression relies on sub-maximal TF recognition motifs (). Layered on top of TF motif affinity is the motif syntax within an enhancer, where the spacing, orientation, and order of the motifs themselves can impact the ability of the enhancer to drive developmental gene expression (). It is also important to recognize that developmental genes are commonly regulated by additional redundant enhancers and ascertaining the contributions of individual enhancers remains an outstanding challenge for the majority of developmentally expressed genes (; Osterwalder et al., 2018).
Some lineage-determining TFs can bind to compact chromatin regions that are largely inaccessible to other factors. These pioneer factors recruit chromatin-remodeling complexes that promote nucleosome eviction, facilitating the subsequent binding of other collaborating TFs and signal effectors (McPherson et al., 1993; ; reviewed in Zaret, 2020). To impact gene expression, TFs recruit transcriptional cofactors to enhancers. Cofactors can in turn modify chromatin states by catalyzing post-translational histone modifications (e.g., P300/CBP, MLL3/4), initiate chromatin remodeling (e.g., BRG1), bridge the gap between promoters and enhancer-bound transcription machinery (e.g., Mediator), or affect the affinity of TF binding at enhancers (Malik and Roeder, 2010; Siggers et al., 2011; Slattery et al., 2011; Krasnov et al., 2016). Despite these advances (and many others), much remains to be learned about the mechanisms underlying the recruitment of pioneer factors to a small subset of genomic sites and the molecular events that follow.
Enhancer activation in development is accompanied by progressive changes at the chromatin level, which in turn can be used to annotate enhancer states. Repressed enhancers are located in nucleosome dense regions. Certain repressed regions are characterized by the post-translational histone modification H3K27me3 which is deposited by the Polycomb repressive complex 2 (PRC2). The binding of pioneer factors and chromatin-remodeling complexes may switch enhancers to a poised state, in which enhancers share many features with those in an active state. Poised enhancers show features of low nucleosome occupancy, limited TF binding, and post-translational histone modifications H3K4me1 and H3K4me2 without the presence of H3K27ac, a histone mark of active developmental enhancers (; Rada-Iglesias et al., 2011; Zentner et al., 2011). These poised developmental enhancers may even retain the repressive mark H3K27me3 (Rada-Iglesias et al., 2011; Zentner et al., 2011). Upon full activation, transcription co-factor P300 and RNA polymerase II are recruited to enhancers, leading to bi-directional transcription of enhancer RNAs and active enhancer regions marked with H3K27ac (reviewed by ; Heinz et al., 2015).
Enhancer activities are influenced by both local chromatin interactions and higher-order chromatin architectures. Eukaryotic genomes are compartmentalized into large self-interacting chromatin domains, termed topologically associated domains (TADs) (; Rao et al., 2014). TADs largely constrain the chromatin span that enhancers search through and define the regulatory domains within which enhancer-promoter interactions most frequently occur (Long et al., 2016). For example, promoter capture Hi-C experiments have revealed that 60–80% of the detected promoter interactions occur within TADs (Javierre et al., 2016; ; Montefiori et al., 2018). Early studies have noticed that TAD boundaries are shared between different cell types and conserved between species (; Vietri Rudan et al., 2015), however, these two concepts have been revised more recently. An increasing number of studies reported dynamic loss and gain of TADs and changes of TAD sizes during differentiation (; ; Zhang et al., 2019). While evolutionarily conserved TADs correspond to regions of conserved synteny harboring important developmental genes and enhancers (Harmston et al., 2017), new analyses have questioned the extent to which TAD boundaries themselves correspond to evolutionary breakpoints (; ; Torosin et al., 2020). The importance of understanding how TADs relate to gene regulation is underscored by the increasing number of experiments showing that the disruption of TAD boundaries and sub-TAD domains can rewire enhancer-promoter interactions and fundamentally change the regulatory environment (Guo et al., 2015; Lupiáñez et al., 2015; ; ; Liang et al., 2020).
In sum, the precise and robust transcriptional regulation that occurs during development is achieved by the complex interplay between enhancers, TFs, co-factors, and epigenetic modifications, which together are organized under higher orders of chromatin architectures.
Heart Enhancers: Fundamental Insights, One Cre at a Time
Studies of heart enhancers initiated from targeted searches around cardiac genes. Putative enhancer regions were screened by “promoter bashing,” in which regulatory regions near the TSS are narrowed down via a series of deletions/mutations to produce overlapping DNA segments that are tested in reporter assays (Table 1). One of the best-studied examples is the mouse Nkx2.5 locus. LacZ reporter assays identified enhancer elements that specifically drove Nkx2.5 expression in different chambers of the hearts, as well as in thyroid, pharynx, and stomach within a 14 kb window around the TSS, revealing previously unappreciated complex enhancer modules underlying the control of cardiac TFs. Similar complexities were seen at genes encoding other cardiac TFs, such as Hand2 (heart and pharyngeal specific enhancers) (McFadden et al., 2000; ; Iklé et al., 2012), Mef2c (anterior heart field and somite specific enhancers) (Wang et al., 2001; ), and Gata4 (lateral mesoderm, endocardium, and endoderm specific) (Rojas et al., 2005, 2009; Schachterle et al., 2012). Although limited in number and biased toward proximal gene promoter regions, these studies (and many others) have revealed fundamental principles and mechanisms underlying cardiac gene regulation.
TABLE 1
| Target genes | Enhancer length | Genomic position | Expression domain | Upstream regulators or function | References |
| Mouse Nkx2.5 | 14 kb | 5′ flanking sequence of TSS | cardiac crescent, ventricles, outflow tract, pharynx, thyroid, stomach | NKX2.5 (negatively regulate this enhancer) | Tanaka et al., 1999 |
| Mouse Nkx2.5 | 4, 3.3 kb | 5′ flanking sequence of TSS | outflow tract, basal portion of the right ventricle, pharynx, thyroid | Tanaka et al., 1999 | |
| Mouse Nkx2.5 | 6 kb | 3′ flanking sequence of TSS | right ventricle | Tanaka et al., 1999 | |
| Mouse Nkx2.5 | 8 kb | [−14, −6 kb] of TSS | medial wall and inner trabeculae of ventricles | Tanaka et al., 1999 | |
| Mouse Nkx2.5 | 2.1 kb, two separate fragments (513, 686 bp) (AR1) | [−9.4, −7.3 kb] of TSS | endogenous cardiac expression of Nkx2.5 | GATA4, MEF2C, NFAT, MZF1 | Lien et al., 1999; ; ; |
| Mouse Nkx2.5 | 505 bp (AR2) | [−3, −2.5 kb] of TSS | anterior cardiac crescent, right ventricle, outflow tract, developing spleen, pharyngeal pouches | GATA, SMAD4, NFAT, ISL1 | Searcy et al., 1998; Liberatore et al., 2002; Lien et al., 2002; Takeuchi et al., 2005; ; Quinodoz et al., 2018 |
| Mouse Nkx2.5 | 2, 1.5 kb | [−10.7, −3.5 kb] of TSS | early heart tube, outflow tract, right ventricle | GATA | Reecy et al., 1999 |
| Mouse Nkx2.5 | 237 bp (G-S) | [−6.2, −5.79 kb] of TSS | cardiac crescent, heart, forebrain | GATA4, SMAD1/4 | |
| Mouse Nkx2.5 | 10 kb (FL) | 5′ flanking sequence of TSS | test in cell lines (10T1/2, P19) | GATA4, SMAD1/4, TBX20 | ; Takeuchi et al., 2005 |
| Mouse Nkx2.5 | 2.6 kb (UH5) | [−16, −14 kb] of TSS (estimated) | heart tube, both atria, left ventricle, foregut | ||
| Mouse Nkx2.5 | 7.3 kb (UH6) | [14, −6 kb] of TSS (estimated) | right ventricle, interventricular septum, atrial ventricular canal | ||
| Chicken Nkx2.5 | 3 kb, 200 bp | [+976 bp, +3.97 kb], [+2.1, +2.3 kb] of TSS | anterior cardiac cresent, outflow tract, right ventricle, pharyngeal arches (test in mouse) | GATA4/5/6, SMAD, YY1 | Lee et al., 2004 |
| Mouse Gata4 | 4.4 kb (G2) | [−45.3, −40.9 kb] of TSS | lateral mesoderm | FOXF1, GATA4, BMP4 | Rojas et al., 2005 |
| Mouse Gata4 | 1.9 kb (G9) | 93 kb upstream of TSS | cardiac crescent, linear heart tube, endocardium | EST factors (ETS1, ERG) | Schachterle et al., 2012 |
| Zebrafish gata4 | 14.8, 12 kb | 5′ flanking sequence of TSS | lateral plate mesoderm, both atrium and ventricle | Heicklen-Klein and Evans, 2004 | |
| Zebrafish gata4 | 7.8, 5.5 kb | 5′ flanking sequence of TSS | ventricle and the bulboventricular valve | Heicklen-Klein and Evans, 2004 | |
| Zebrafish gata4 | 3 kb (DR1), 1.3 kb (DR1A) | [−11, −8 kb] of TSS | lateral plate mesoderm, both atrium and ventricle | TBX | Heicklen-Klein and Evans, 2004 |
| Chicken GATA5 | 500 bp | [−5, −4.5 kb] of TSS | cardiac crescent, septum trans-versum and epicardium, ventricle, AV canal (test in mice) | MacNeill et al., 2000 | |
| Mouse Gata6 | 6.8, 1.8 kb | [−4.3, +2.5 kb], [−4.3, −2.5 kb] of TSS | cardiac cresent, high expression in outflow tract | NKX2.5 | Molkentin et al., 2000 |
| Chicken GATA6 | 1.4 kb | 6.2 kb upstream of TSS | cardiac crescent, high expression in the outflow tract (test in mouse) | NKX2.5 | |
| Chicken GATA6 | 10 kb | [−9.2, +0.8 kb] of TSS | cardiac specific (test in mice) | He and Burch, 1997 | |
| Chicken GATA6 | 2.3, 1.5 kb | [−1.5, +0.8 kb], [−1.5 kb, 0] of TSS | posterior region of the heart field, atrioventricular conduction system (test in mice) | Retinoic acid | He and Burch, 1997; |
| Chicken GATA6 | 317, 187, 102, 47 bp | [−1.4, −1.1 kb] of TSS | atrioventricular conduction system (test in mice) | GATA | |
| Mouse Hand2 | 1.5 kb | [−4.2, −2.7 kb] of TSS | cardiac crescent, right ventricle, outflow tract | GATA | McFadden et al., 2000 |
| Mouse Mef2c | 6, 3.9 kb, 449 bp | [+16.3, +22.5 kb] of TSS | anterior (second) heart field | GATA4, ISL1, NKX2.5, TBX20, TBX1 (negative regulator) | ; Takeuchi et al., 2005; ; Pane et al., 2018 |
| Mouse Hey2 | 2.5, 1.6 kb, 649 bp | 211 kb upstream of TSS | cardiac crescent, ventricle and outflow tract | TBX20, GATA4 | Ihara et al., 2020 |
| Zebrafish hey2 | 626 bp (aCNE21) | 24 kb upstream of TSS | distal linear heart tube, ventricle, outflow tract | ; Yuan et al., 2018 | |
| Mouse Tbx1 | 200 bp (require another non-cardiac element) | [−12.8, −12.6 kb] of TSS | second heart field, right ventricle, outflow tract, pulmonary trunk, and pulmonary valves | FOX (likely FOXC1 or FOXC2) | Maeda et al., 2006 |
| Human TBX5 | 368 bp (enhancer 2) | 380 kb downstream of TSS | both ventricles and atria | Harbor a CHD-associated variant | Smemo et al., 2012 |
| Human TBX5 | 3.5 kb (enhancer 9) | 140 kb downstream of TSS | ventricles, interventricular septum, atrioventricular canal | Smemo et al., 2012 | |
| Human TBX5 | 5 kb (enhancer 16) | 9 kb upstream | ventricles, interventricular septum, atrioventricular canal, and weakly in atria | Smemo et al., 2012 | |
| Mouse Isl1 | 2.9 kb | 120 kb downstream | embryonic and adult sinoatrial node (SAN) | SAN hypoplasia and sinus arrhythmia in enhancer knockout, contain SNPs associated with heart rate | |
| Mouse Fgf8 | 900 bp | [−5.4, −4.5 kb] of TSS | outflow tract, pharyngeal arches | TBX1 | Hu et al., 2004 |
| Mouse Fgf10 | 1.7 kb | [+44, +46 kb] of TSS | anterior second heart field, pharyngeal mesoderm | TBX1, NKX2.5 (negative), ISL1 | Watanabe et al., 2012 |
| Mouse Srf | 1 kb, 541 bp | 3′ UTR sequence | cardiac crescent, heart tube, tail | TBX2 TBX5, TIP60 |
Functionally characterized enhancer regions near cardiac genes.
Establishing Molecular Cascades Regulating Heart Development
Enhancers represent information hubs that integrate multiple upstream regulatory inputs such as lineage-determining master TFs and signaling effectors. Dissecting the transcription factors that bind to enhancers unveils these direct upstream regulators (Figure 1 and Table 1). By combining motif mutagenesis, gel shift, and transgenic assays, Nkx2.5 enhancer studies revealed that GATA4 and SMAD-mediated BMP signaling directly activated Nkx2.5 expression through multiple enhancer regions (Searcy et al., 1998; Lien et al., 1999, 2002; Liberatore et al., 2002; ) (Figure 1). Dissections of Nkx2.5 enhancers in the following years added ISL1, TBX20, MEF2C, and NFAT into direct upstream regulators that collectively drove Nkx2.5 expression in cardiac cells (Takeuchi et al., 2005; ; ). Furthermore, mining known heart enhancers can also lead to discoveries of novel cardiac regulators. For example, MZF1, previously known as a hematopoietic TF, was found to bind to an Nkx2.5 enhancer from in silico motif analysis and validated in embryonic stem cell (ESC) differentiation. Overexpression of MZF1 at different stages of cardiac differentiation revealed its novel, stage-dependent roles in cardiogenesis ().
FIGURE 1
Through similar enhancer dissection, the upstream signals of many other cardiac TFs have been identified (Table 1 and Figure 1). For example, the lateral mesoderm expression of mouse Gata4 relies on transcriptional inputs from FOXF1, BMP4, and its autoregulation (Rojas et al., 2005), while its expression in endocardia requires binding of ETS factors such as ETS1 and ERG (Schachterle et al., 2012). The anterior heart field (AHF) expression of Mef2c is positively regulated by GATA4, ISL1, and TBX20 and repressed by TBX1 through an intronic enhancer (
Cardiac TF Crosstalk
Enhancer activation requires the cooperative binding of multiple TFs, therefore studying heart enhancers reveals cooperation and competition between these upstream factors. By co-expressing different combinations of factors together with a specific enhancer, the synergistic effect of factors in activating the enhancer can be revealed by quantitative measures like luciferase assays. Using this type of approach, GATA4 and SMAD1/4 were found to work as mutual co-activators in activating Nkx2.5 expression through a distal enhancer (commonly referred to as the G-S enhancer) (
Putting Enhancers to Work
Besides providing direct evidence for building cardiac transcriptional networks, validated cardiac enhancers also frequently serve as genetic tools to label a specific cardiac population of interest for developmental studies. Transgenic mice in which Cre recombinase expression is driven by the Mef2c AHF enhancer have been used to determine anterior heart field derived structures and conditionally knock-out many developmental genes (Mef2c, Tbx1, β-catenin, Ezh2) to reveal their specific roles in anterior heart field development and congenital heart disease (Verzi et al., 2005;
In sum, deeply dissecting cardiac enhancers reveals both molecular tools for visualizing, isolating, and manipulating cardiac populations as well as cis- and trans-regulatory mechanisms that control cardiac gene expression.
Unmasking Heart Enhancers With Comparative and Functional Genomics
Enhancer Hunting: Tools of the Trade
Comparative genomics has long been used to identify putative enhancer regions (Tagle et al., 1988;
Although CNEs are enriched for developmental enhancers, the vast majority of enhancers appear to evolve more rapidly, with many being lineage- or species-specific. This feature has been demonstrated in many different tissues or cell types and in both vertebrates and invertebrates (Odom et al., 2007; Kunarso et al., 2010; Schmidt et al., 2010b; Mikkelsen et al., 2010;
Over the past 15 years, large scale genomic assays have enabled enhancer discoveries at an unprecedented scale (Table 2). In particular, chromatin immunoprecipitation with high-throughput sequencing (ChIP-seq) can locate enhancers by profiling the co-occupancy of lineage-specific TFs, binding of co-factors, or post-transcriptional modifications that marks active enhancers (reviewed in
TABLE 2
| Method category | Method strategy | Description | References |
| ChIP-seq (detect DNA-binding factor occupancy and histone modification profiles) | Co-factors (EP300, Mediator) | Assays enhancers mediated by specific co-factors; TFs need not be specified in advance. | |
| Co-occupancy of multiple TFs | Reveals specific trans factors but requires specific antibodies for each factor and often each species. Typically requires large numbers of nuclei. | He et al., 2011, 2014; Luna-Zurita et al., 2016; | |
| Active histone marks (H3K27ac, H3K4me1) | Robust antibodies that work across metazoans; reveals enhancer states;requires less input than for TFs. | Wamstad et al., 2012; Nord et al., 2013; He et al., 2014 | |
| Enzyme tethering ChIP alternative (use factor-mediated in-situ genome fragmentation to profile epigenome) | CUT&RUN (pA-MNase fusion protein) | Unfixed in-situ procedure, requires lower cell numbers (∼100 for histone modification) and less sequencing reads | Skene and Henikoff, 2017; Meers et al., 2019 |
| CUT&Tag (pA-Tn5) | Similar to CUT&RUN with a simpler barcoding step; streamlined workflow in a single tube; works on low cell numbers or even single cells | Kaya-Okur et al., 2019; Henikoff et al., 2020 | |
| CUTAC (pA-Tn5, low salt) | Similar to CUT&Tag with a small modification that detects accessible chromatin in parallel with adjacent histone modifications | Henikoff et al., 2020 | |
| Accessible chromatin profiling (detect nucleosome-depleted regions that are enriched for enhancers) | DNase-seq | High quality TF footprintscan be generated. | Thurman et al., 2012; Vierstra et al., 2014, 2020 |
| ATAC-seq | Simple and robust method that requires low cell numbers, widely applied; can be used on frozen sections; produces a comprehensive list of where CREs may be located. | ||
| Nascent RNA sequencing run-on assays (depict the real-time activity of RNA polymerases and detect eRNAs) | GRO-seq | Detect actively transcribed eRNAs which is a hallmark of active enhancers | |
| PRO-seq | Refined version of GRO-seq that uses biotinylated nucleotide to reach nucleotide-resolution, low background, and large dynamic ranges | Kwak et al., 2013; | |
| ChRO-seq | Similar to PRO-seq but use chromatin as starting materials; can be applied to solid tissues and samples with degraded RNAs | ||
| Chromosome conformation capture (use proximity ligation and detect enhancer-promoter interaction) | Hi-C | Maps genome-wide chromatin contacts (‘all-to-all’); requires substantial sequencing to reveal local enhancer-promoter interactions | Lieberman-Aiden et al., 2009 |
| Promoter capture Hi-C | Maps promoter-centric chromatin interactions; requires less reads for detecting promoter-enhancer interactions | Mifsud et al., 2015; Schoenfelder et al., 2015 | |
| ChIA-PET | Detect chromatin interactions mediated by a specific DNA-binding factor; can enrich rare factor-specific chromatin interactions | ||
| HiChIP& PLAC-seq (Use in-situ Hi-C followed by ChIP) | Detects factor-centric chromatin interaction similar to ChIA-PET but require 10-fold to 100-fold fewer cells, also more robust and less time-consuming | ||
| 4C | Identifies all genomic regions that interacts a reference locus (‘one-to-all’); can be used for studying specific enhancers | Simonis et al., 2006 |
Genomic approaches for enhancer mapping.
Chromatin accessibility profiling provides a comprehensive view of the candidate regions most likely to harbor CREs, making them arguably the most widely used assay to identify putative enhancers (Thurman et al., 2012;
After discovering a distal putative enhancer, one of the most pressing questions is to discover what gene or genes it associates within a cell type and condition of interest. To address this, chromosome conformation capture (3C) based assays (including 4C, 5C, HiChIP, promoter capture Hi-C, and Hi-C) are commonly used to characterize enhancer-promoter interactions (
These widely used genome-scale assays, each with their own strengths (Table 2), continue to reveal new insights into enhancer location, activity and function. The increasing number of high-quality datasets are also creating new opportunities and challenges for integrative data analysis that will further expand our understanding of metazoan heart development and human disease.
Heart Enhancers: From Genome-Wide Mapping to Metazoan Regulatory Logic
The development of ChIP-chip, ChIP-seq, and other genomic techniques has enabled genome-wide enhancer discoveries and analysis of distinct cardiac samples obtained from diverse model systems (Table 3). Pioneering studies in Drosophila using ChIP-chip against master regulators (Twi, Tin, Mef2, Bag, Bin, Doc, and Pnr) and signaling effectors (dTCF and pMad) required for the specification of cardiac mesoderm revealed fundamental principles of combinatorial TF binding dynamics and TF-signaling interactions at cardiac enhancers (Zinzen et al., 2009; Junion et al., 2012). These Drosophila cardiac TF mapping studies, together with a comparative analysis of Twi, Tin, Mef2, Bin, and Bap in two distant Drosophila species, underscore the conserved presence of combinatorial TF binding, even when the underlying DNA sequence has changed (Khoueiry et al., 2017). The Junion et al. (2012) study led to a “transcription factor collective” model of TF binding where TFs use both protein-DNA and protein–protein interactions to regulate gene expression (reviewed by Spitz and Furlong, 2012), which was later supported by the comparative Khoueiry et al. (2017) study.
TABLE 3
| Method | Species | Factor | Sample | Condition | Stage | References |
| BiTS-ChIP-Seq | Drosophila | H3, H3K4me3, H3K4me1, H3K27ac, H3K27me3, H3K36me3, H3K79me3 | Mesoderm | WT | stages 10–11 (6–8 h AEL, cardiac mesoderm specified) | |
| ChIP-seq | Zebrafish | H3.3 | myl7:GFP+ cardiomyocytes | Uninjured, 14 days post ablation, 7 days post Nrg1 treatment | Adult | |
| ChIP-seq | Zebrafish | H3K27ac | myl7:GFP+ cardiomyocytes | Uninjured, 14 days post ablation | Adult | |
| ChIP-seq | Mouse | H3K27ac, H3K4me1, H3K4me3, H3K27me3 | ESCs, ESC-differentiated cells | WT | ESCs, mesoderm, cardiac precursors, cardiomyocytes | Wamstad et al., 2012 |
| ChIP-seq | Mouse | H3K27ac | Hearts | WT | E11.5, E14.5, E17.5, P0, P7, P21, P56 | Nord et al., 2013 |
| ChIP-seq | Mouse | H3K4me1, H3K27me3, H3K4me3 | Ventricle | WT | E12.5 and adult | He et al., 2014 |
| ChIP-seq | Mouse | H3K27ac | Ventricle | WT, GATA4 KO | E12.5 (WT, GATA4 KO), adult (normal) | |
| ChIP-seq | Mouse | H3K27ac | Heart | WT | E12.5 | Zhou et al., 2017 |
| ChIP-seq | Mouse | H3K27ac | iCLM (induced cardiac-like myocytes) reprogrammed from MEF | Transfected with GMT, GHMT, AGHMT or mock control | Day 2 and 7 in reprogramming | Hashimoto et al., 2019 |
| ChIP-seq | Mouse | H3K27ac | iCLM (induced cardiac-like myocytes) reprogrammed from MEF | Transfected with single factors | Day 2 in reprogramming | |
| ChIP-seq | Mouse | H3K27ac | Ventricle, atrium | WT | P4 | |
| ChIP-seq | Human | H3K4me3, H3K27me3, H3K36me3 | ESCs, ESC-differentiated cells | WT | pluripotent cells, mesodermal progenitors, specified tripotential cardiovascular progenitors, committed cardiovascular cells, definitive cardiovascular cells | Paige et al., 2012 |
| ChIP-seq | Human | H3K4me3, H3K36me3, H3K27ac, H3K27me3 | iPSC-differentiated cells | WT, GATA4_G296S | iPSC-derived cardiomyocytes | |
| ChIP-seq | Human | H3K27ac, H3K9ac, H3K4me3, H3K4me1, H3K36me3 | Left ventricle | Healthy donor and patients with heart failure | fetal, infant, adult (non-failing and failing heart) | |
| ChIP-seq | Human | H3K27ac | Left ventricle | healthy donors and patients with dilated cardiomyopathy | Adult | Spurrell et al., 2019 |
| ChIP-seq | Human | H3K27ac | ESCs, ESC-differentiated cells | WT | ESCs, mesodermal cells, cardiac mesodermal cells, cardiac progenitors, primitive cardiomyocytes, and ventricular cardiomyocytes | Zhang et al., 2019 |
| ChIP-seq | Human | H3K4me1, H3K4me2, H3K4me3, H3K27ac, H3K27me3, H3K9me3, H3K36me3 | Heart | Healthy donor | CS13, CS14, CS16, CS17, CS18, CS19, CS20, CS21, CS23 (Carnegie stage, corresponding to PCW 4–8) | Vanoudenhove et al., 2020 |
| ChIP-chip | Drosophila | Twist, Tinman (Nkx2.5) | Whole embryo | WT | Stage 5–7, stage 8–9 (dorsal mesoderm specified), stage 10–11 (cardiac mesoderm specified) | Zinzen et al., 2009 |
| ChIP-chip | Drosophila | Mef2 | Whole embryo | WT | Stage 5–7, stage 8–9, stage 10–11 stage 12–13, stage 13–15 | |
| ChIP-chip | Drosophila | Bagpipe | Whole embryo | WT | Stage 10–11 | |
| ChIP-chip | Drosophila | Biniou | Whole embryo | WT | Stage 10–11, stage 12–13, stage 13–15 | |
| ChIP-chip | Drosophila | Dorsocross, Pannier, dTCF, and pMad | Whole embryo | WT | Stage 8–9, stage 10–11 | Junion et al., 2012 |
| BiTS-ChIP-seq | Drosophila | Mef2, Rpb3-Pol II | Mesoderm | WT | stages 10–11 | |
| ChIP-seq | Drosophila | Mef2 | Whole embryo | WT | ||
| ChIP-seq | Drosophila melanogaster and Drosophila virilis | Twist | Whole embryo | WT | Stage 5–7, stage 8–9, stage 10–11 | Khoueiry et al., 2017 |
| Tinman | Stage 8–9, stage 10–11 | |||||
| Mef2 | Stage 5–7, stage 8–9, stage 10–11 stage 12–13, stage 13–15 | |||||
| Bagpipe | Stage 10–11 | |||||
| Biniou | Stage 10–11, stage 12–13, stage 13–15 | |||||
| ChIP-seq | Mouse | P300 | Heart | WT | E11.5 | |
| ChIP-seq | Mouse | P300 | Heart | WT | P2 | May et al., 2012 |
| ChIP-seq | Mouse | GATA4 (flag or biotin-tagged) | Ventricle | WT | E12.5 | He et al., 2014 |
| ChIP-seq | Mouse | GATA4 (flag or biotin epitope-tagged) | Ventricle | Normal, banding (surgically placed ligature around the aorta), sham | Adult | |
| ChIP-seq | Mouse | GATA4, TBX3, NKX2.5, P300 | Heart | WT | Adult | van den Boogaard et al., 2012 |
| ChIP-seq | Mouse | HAND2 (flag-tagged) | Limb bud, hearts, branchial arches | WT | E10.5 | Osterwalder et al., 2014 |
| ChIP-seq | Mouse | NKX2.5 | Heart | WT | E11.5 | |
| ChIP-exo | Mouse | GATA4, NKX2.5, and TBX5 | ESCs, ESC-differentiated cells | WT, NKX2.5 KO, TBX5 KO, double KO | cardiac precursors and cardiomyocytes | Luna-Zurita et al., 2016 |
| ChIP-seq | Mouse | P300 (biotin-tagged) | Heart | WT | E12.5, Adult | Zhou et al., 2017 |
| ChIP-seq | Mouse | P300 (biotin-tagged) | Endocardial and endothelial cells in the heart | WT | Adult | |
| ChIP-seq | Mouse | CTCF | Left ventricle (isolated cardiomyocytes) | WT, CTCF KO | Adult | Rosa-Garrido et al., 2017 |
| ChIP-seq | Mouse | HAND2 (flag-tagged) | Heart | WT | E10.5 | Laurent et al., 2017 |
| ChIP-seq | Mouse | TBX20 (GFP-tagged) | Heart | WT | E11.5 | |
| ChIP-seq | Mouse | GATA4, HAND2 (3XTy1 tag), MEF2C (3XTy1 tag), TBX5 | iCLM (induced cardiac-like myocytes) reprogrammed from MEF | Transfected with GHMT, AGHMT or single factors | Day 2 in reprogramming | Hashimoto et al., 2019 |
| ChIP-seq | Mouse | GATA4, MEF2C (3XTy1 tag), TBX5 | iCLM (induced cardiac-like myocytes) reprogrammed from MEF | Transfected with GMT | Day 2 in reprogramming | |
| ChIP-seq | Mouse | GATA4, TBX5 | Ventricle | WT | P4 | |
| ChIP-seq | Mouse | MEF2A, MEF2C, NKX2.5, SRF, TBX5, TEAD1 (biotin -tagged) | Heart | WT | E12.5 | |
| ChIP-seq | Mouse | MEF2A, NKX2.5, SRF, TBX5, TEAD1 (biotin-tagged) | Heart | WT | Adult (P42) | |
| ChIP-seq | Human | NKX2.5, GATA4, TBX5, SRF, MEF2A, P300 (all TFs biotin-tagged) | HL1 cardiomyocyte cell line | WT | cell line | He et al., 2011 |
| ChIP-seq | Human | P300 | Heart | WT | Fetal (gestational week 16), adult | May et al., 2012 |
| ChIP-seq | Human | GATA4, TBX5, MED1 | iPSC-differentiated cells | WT, GATA4_G296S | iPS-derived cardiomyocytes | |
| ChIP-seq | Human | HEY2, NR2F2, and TBX5 | iPSC-differentiated cells | WT | cardiomyocytes | |
| ChIP-seq | Human | CTCF | ESCs, ESC-differentiated cells | WT | ESCs, mesodermal cells, cardiac mesodermal cells, cardiac progenitors, primitive cardiomyocytes, and ventricular cardiomyocytes | Zhang et al., 2019 |
Genome-wide metazoan heart enhancer profiling datasets generated using chromatin immunoprecipitation of post translational histone modifications, transcription factors, and cofactors.
Data from consortiums (ENCODE, FANTOM, and Roadmap Epigenomics Projects) are not listed. The table separates post translational histone modifications from TF/cofactor data. For each data type, the experiments are sorted by species first and then by publication date.
To demarcate the location of putative enhancers active in embryonic and adult hearts, pioneering mammalian studies performed ChIP-seq for the histone acetyltransferase EP300 and the active post-translational histone modification H3K27ac (
Like in Drosophila, the combinatorial binding of cardiac TFs defines mammalian heart enhancers (He et al., 2011;
To study cardiac enhancer dynamics across multiple stages of in vitro cardiac differentiation or in vivo development, several studies from individual labs as well as consortiums, have utilized robust genome-wide assays that do not rely on mapping specific transcription factors, namely ChIP-seq for histone modifications (Paige et al., 2012; Wamstad et al., 2012; Nord et al., 2013; Vanoudenhove et al., 2020), and DNase-seq and ATAC-seq for chromatin accessibility (
Functional insights into cardiac enhancer regions continue to be made by studying TF occupancy and chromatin states upon the perturbation of cardiac TFs or signaling pathways in multiple organisms (e.g., Gata4, gata5, Nkx2.5, Tbx5/tbx5, Tbx20, Hand2/hand2, Isl1, Foxf, Fgfr, Mek, and Ras) (He et al., 2014; Luna-Zurita et al., 2016;
Heart Enhancers in Space: Chromatin Interactions and Architectures
Heart enhancer activity not only requires proper TF binding, but is under the control of local chromatin interactions and higher-order chromatin architectures. Several groups have conducted promoter capture Hi-C in ESC/iPSC-derived cardiomyocytes or adult hearts to map enhancer-promoter interactions (
The importance of chromatin interactions and architecture in heart development and function is also revealed by the essentiality of genome organizing factors such as CTCF and the cohesin complex. CTCF knock-out in cardiac progenitor cells leads to severe defects in cardiac cell maturation due to the disruption of enhancer-promoter interaction and subsequent misregulation of cardiac genes (
Enhancing Enhancers With Enhancer-Associated RNAs
Upon activation, many enhancers are transcribed into non-coding RNAs, which are broadly referred to as enhancer RNAs (eRNAs). The expression of eRNAs is well correlated with their putative target gene expression (Kim et al., 2010; Kaikkonen et al., 2013; Li et al., 2013;
Though early discoveries described eRNAs as short, non-polyadenylated, bidirectionally transcribed RNAs (Kim et al., 2010;
The roles of eRNAs and lncRNAs in the contexts of heart development have been explored by many studies (
The field of enhancer-associated ncRNAs in heart development has many unanswered questions. Future studies that use chromatin run-on assays (GRO-seq, PRO-seq) or generate deeply sequenced RNA-seq datasets coupled with enhancer annotations should help to understand the dynamic changes of eRNAs in development. Functional experiments such as those use RNA targeting Cas protein (Cas13) (
Heart Enhancers: Keeping Track of Time
As the activity of enhancers are not only tissue-specific but also stage-specific, it is important to obtain high-resolution temporal profiles of heart enhancers to truly understand their function. This is specifically highlighted by the in vitro cardiac differentiation study from Wamstad et al. (2012), which showed that enhancers active in ESC, mesoderm progenitors, cardiac progenitors, and cardiomyocytes were largely non-overlapping (Wamstad et al., 2012). Consistently, Luna-Zurita et al. (2016) discovered thousands of GATA4, NKX2.5, and TBX5 binding sites were specific to either cardiac progenitor cells or cardiomyocytes. Similar results have also been reported for in vivo development, for example, 80% of the GATA4 binding sites in fetal heart are not occupied by GATA4 in adult heart (He et al., 2014).
Since the heart is the first organ formed in embryogenesis, the embryonic stage that is required to capture the initial phase of cardiogenesis is especially early in development, and is likely during early gastrulation (Scott, 2012;
TABLE 4
| Methods | Species | Sample | Condition | Stage | References |
| Hi-C | Mouse | Left ventricle (isolated cardiomyocytes) | Control, Transverse Aortic Constriction, CTCF KO | Adult | Rosa-Garrido et al., 2017 |
| Hi-C | Human | ESCs, ESC-differentiated cells | WT | ESC-derived mesendoderm cells | |
| Hi-C | Human | Left ventricle | WT | Adult | Leung et al., 2015 |
| Hi-C | Human | Right ventricle | WT | Adult | Schmitt et al., 2016 |
| PCHi-C | Human | iPSCs, iPSC-differentiated cells | WT | iPSC, iPSC-derived cardiomyocytes | Montefiori et al., 2018 |
| PCHi-C | Human | ESCs, ESC-differentiated cells | WT | ESC-derived cardiomyocytes | |
| PCHi-C | Human | Left ventricle | WT | adult | Jung et al., 2019 |
| Hi-C | Human | ESCs, ESC-differentiated cells, iPSCs, iPSC-differentiated cells | WT | ESCs, iPSCs, mesoderm, cardiac progenitors, cardiomyocytes, fetal heart | |
| Hi-C | Human | ESCs, ESC-differentiated cells | WT | ESCs, mesodermal cells, cardiac mesodermal cells, cardiac progenitors, primitive cardiomyocytes, and ventricular cardiomyocytes | Zhang et al., 2019 |
Chromatin interaction datasets used for annotating heart enhancers.
Data from large consortiums (ENCODE, FANTOM, and Roadmap Epigenomics Projects) are not listed. Datasets are sorted by species first and then by publication dates.
TABLE 5
| Methods | Species | Samples | Condition | Stage | References |
| ATAC-seq | Ciona | B7.5 lineage | WT | 6 hpf (native mesoderm),18 hpf (committed heart and pharyngeal muscle precursors) | Racioppi et al., 2019 |
| ATAC-seq | Ciona | B7.5 lineage | WT, Fgfr dominant-negative, Mek constitutively active, Foxf-CRISPR, M-Ras constitutively active | 10 hpf (multipotent cardiopharyngeal progenitors) | |
| ATAC-seq | Zebrafish | myl7:GFP+ cardiomyocytes | WT, gata5 -/-, hand2 -/-, tbx5 -/- mutants | 72 hpf | Pawlak et al., 2019 |
| ATAC-seq | Mouse | Heart | WT | E12.5 | Zhou et al., 2017 |
| ATAC-seq | Mouse | Heart | WT | P1, P14, P56 | Quaife-Ryan et al., 2017 |
| ATAC-seq | Mouse | endocardial cells | WT and TBX20 KO | E12.5 | |
| ATAC-seq | Mouse | Nkx2-5+ cardiac progenitor cells | WT | E7.5, E8.5, E9.5 | Jia et al., 2018 |
| ATAC-seq | Mouse | Isl1+ cardiac progenitor cells | WT and Isl1 KO | E8.5, E9.5 | |
| ATAC-seq | Mouse | Isl1+/CD31+, Isl1+/CD31- cardiac progenitor cells | WT | E8.5, E9.5 | |
| ATAC-seq | Mouse | Isl1+ cardiac progenitor cells | Nkx2.5 overexpression in Isl1+ cells | E9.5, E12.5 | |
| Single-cell ATAC-seq | Mouse | Isl1+ cardiac progenitor cells | WT | E8.5, E9.5 | |
| Omni-ATAC-seq | Mouse | Heart | WT | Adult | Liu et al., 2019 |
| ATAC-seq | Mouse | Ventricle cardiomyocytes | WT | E12.5 | |
| ATAC-seq | Mouse | Cardiac pacemaker cells (PCs), right atrial cardiomyocytes (RACMs) | WT | Neonatal (P0-P2) | |
| Single-cell ATAC-seq | Mouse | Ventricle | myocardial infarction (MI) or sham surgeries | P1, P8 (3days post surgeries for both) | Wang et al., 2020 |
| ATAC-seq | Human | ESCs, ESC-differentiated cells | WT | ESCs, mid primitive streak, lateral mesoderm, cardiac mesoderm | Loh et al., 2016 |
| ATAC-seq | Human | iPSC-differentiated cells | WT, GATA4_G296S | iPS-derived cardiac progenitor cells | |
| ATAC-seq | Human | ESCs, ESC-differentiated cells, iPSCs, iPSC-differentiated cells | WT | ESCs and iPSCs, mesoderm, cardiac mesoderm, cardiomyocyte | Liu et al., 2017 |
| ATAC-seq | Human | ESCs, ESC-differentiated cells, iPSCs, iPSC-differentiated cells | Control and INN (isotretinoin) treatment | ESCs and iPSCs, mesoderm, cardiac mesoderm | Liu et al., 2018 |
| ATAC-seq | Human | ESCs, ESC-differentiated cells | WT | ESCs, mesoderm, cardiac progenitors, cardiomyocytes | |
| ATAC-seq | Human | ESC-differentiated sinoatrial node-like pacemaker cells (SANLPC), ventricle-like cardiomyocytes (VLCM), | WT | ESC-differentiated cardiomyocytes | van Eif et al., 2020 |
Chromatin accessibility datasets used for annotating heart enhancers.
Data from large consortiums (ENCODE, FANTOM, and Roadmap Epigenomics Projects) are not listed. Datasets are sorted by species first and then by publication dates.
A few recent in vivo studies confirm the observations made from in vitro differentiation that enhancer-associated chromatin states are highly dynamic, especially during early cardiac lineage specification. A recent study that profiled mouse Nkx2.5+ cardiac progenitor cells revealed major changes in chromatin accessibility between E7.5 and E8.5 but only minor differences between E8.5 and E9.5 (Jia et al., 2018). This suggests that early lineage fate transitions may be accompanied by major changes of chromatin states, which become more stabilized in committed cell types. Similar trends are observed in cardiopharyngeal lineage specification in the tunicate Ciona, in which most significant chromatin changes occur between the transition from mesoderm progenitors to cardiopharyngeal progenitors compared to later stages (Racioppi et al., 2019). These examples reveal intriguing dynamics of the enhancers involved in early cardiac lineage decisions, however, much remains to be explored. Filling this knowledge gap, especially in the context of developing embryos, can bring valuable insights into key cellular events in early cardiogenesis.
Evolutionary Mysteries of Heart Enhancers
Intriguing results have emerged from evolutionary studies of heart enhancers. Although the TFs controlling heart enhancers are highly conserved, validated heart enhancers show weak DNA constraint compared to brain enhancers identified at the same developmental stage (E11.5) (
It remains an open and intriguing question how heart enhancers that lack evolutionary conservation work together with many conserved cardiac TFs to orchestrate the development of the heart. Several reasons may contribute to this phenomenon. First, it has been demonstrated by many studies that enhancers are rapidly evolving with pervasive turnovers of TF binding sites (TFBSs) (Kunarso et al., 2010; Mikkelsen et al., 2010; Schmidt et al., 2010b;
Second, an increasing number of studies indicate that the conservation of enhancers active in early embryonic development follows an hour-glass like pattern (
FIGURE 2

Discovering conserved heart enhancers during early heart development: a case study. (A) Enhancers that are active at different stages of heart development show different evolutionary constraints. In mouse, enhancers that are active in mesoderm progenitors show higher sequence conservation than enhancers active in ESC and E11.5 embryonic hearts. But conservation levels of enhancers that active during the transition of mesoderm progenitors to cardiac progenitors and cardiac progenitors to cardiomyocytes remain less characterized. aCNEs, the accessible chromatin shared between zebrafish and human (or zebrafish and mouse) were identified within the mesoderm to cardiac progenitor transition (Yuan et al., 2018). Schematics generated based on Figure 5 (Nord et al., 2013). (B) Schematics showing sequence homology and shared enhancer signatures for aCNE1 locus across multiple species. aCNE1 was first discovered as an accessible chromatin region specific for an early cardiac progenitor-enriched population in zebrafish. Gray lines indicate the existence of orthologous sequences to aCNE1 in the given species (based on CNEs identified in Hiller et al., 2013). In mouse, aCNE1 regions are co-occupied by multiple cardiac TFs in cardiac cells (based on data from Luna-Zurita et al., 2016; Laurent et al., 2017). Human aCNE1 region shows chromatin accessibility in cardiac progenitor cells (based on data from Paige et al., 2012). The stickleback and the frog icons were created by Milton Tan and Soledad Miranda-Rottmann, respectively, and shared through (http://phylopic.org/) under the following license (https://creativecommons.org/licenses/by/3.0/). (C) Genome browser view of aCNE1 in zebrafish (ZaCNE1) and human (HaCNE1) genome. aCNE1 is located 108 kb upstream of hand2 in the zebrafish genome and 406 kb upstream of HAND2 in the human genome. Yellow boxes highlight the genes flanking aCNE1, indicating the conserved synteny that aCNE1 resides in. ATAC-seq data from Yuan et al. (2018) is plotted for ZaCNE1 and promoter capture Hi-C data from Montefiori et al. (2018) is plotted for HaCNE1. Note that aCNE1 display conserved cardiac-specific activity in both zebrafish (accessibility) and human (interacting with cardiac gene HAND2). ZaCNE1 and HaCNE1 shares an aligned GATA motif, the mutation of which can be used to determine if the activity of aCNE1 depends on this GATA motif. (D) Functional enhancer assays of WT and GATA motif mutated zebrafish and human aCNE1 sequence in zebrafish embryos. Candidate sequences are cloned into an enhancer vector to drive GFP expression. The whole cassette will be chromatinized after injecting into zebrafish embryos. For both ZaCNE1 and HaCNE1, GATA motif mutation leads to decreased enhancer activity compared to the respective WT sequences. This example illustrates that human and zebrafish aCNE1 share conserved activity and regulation despite less than 60% sequence identity. Schematics generated based on data from Yuan et al. (2018). Parts of this figure were created with BioRender.com.
To explore the existence of pre-cardiac enhancers that could contribute to the initiation of cardiac gene regulatory networks, we recently characterized the open chromatin landscape of a cardiac-enriched population in zebrafish embryos before the expression of the canonical cardiac marker nkx2.5 (Yuan et al., 2018). This approach allowed us to detect cardiac CREs that were primed early in development prior to cardiac lineage commitment. We present this work in Figure 2 as a general example of how comparative genomic resources in combination with epigenomic profiling in two or more species can give insight into functionally conserved developmental enhancers. To determine to what extent deeply conserved CREs were involved in early heart development we exploited conserved non-coding element (CNE) datasets established using both direct alignment and indirect approaches (Hiller et al., 2013;
In sum, despite the overall rapid evolution of heart enhancers, a small fraction of deeply conserved heart enhancers likely contributes to the regulation of early cardiogenesis. The lack of overt sequence conservation in heart enhancers may be partially due to the rapid turnover of TFBSs. On the other hand, variants in heart enhancers that alter gene expression are likely to contribute to morphological differences of cardiac structures between species.
Heart Enhancers: One Cell at a Time
Currently, most of the data for annotating heart enhancers was generated at the bulk population level (Tables 3–5); however, both in vitro differentiated cardiac cells and animal hearts contain heterogeneous populations (reviewed in Paik et al., 2020). This was largely due to the challenges in isolating closely related developmental lineages and collecting enough material from early embryos for enhancer profiling. But as enhancer activity is highly context-specific, the existing data bias likely limits the discoveries of enhancers that are active only in specific subpopulations (e.g., SHF progenitors, endocardial cells, cardiac smooth muscle cells, etc.) or at certain stages.
Rapid advances in single-cell genomics techniques have brought unprecedented opportunities to circumvent the difficulties in cell type isolation. Specifically, single-cell ATAC-seq (scATAC-seq) has become more and more commonly used in delineating cell-type-specific CREs within diverse cellular populations (
Furthermore, with single-cell multimodal omics being selected as the Methods of the Year 2019 (Nature Methods, 2020), techniques for simultaneous measuring multiple modalities in the same single cells are blooming rapidly. Related to epigenomics, it has become possible to simultaneous profile accessible chromatin and transcriptome (
Computing Heart Enhancers
With the rapid accumulation of hundreds of epigenomic and transcriptomic datasets from cardiac tissues, efforts have been made toward compiling them and extract sequence features from known cardiac enhancers to predict unknown ones.
Several studies have explored how including different genomics features in training models could affect their performance in enhancer prediction. A study in Drosophila added ChIP signals on top of sequence motifs into their classifiers and found this combined strategy significantly boosted the prediction accuracy of cell-type-specific cardiac enhancers than motif sequence alone (
Heart Enhancers in Cardiovascular Disease
Heart diseases are a leading cause of death worldwide (Mozaffarian et al., 2015). As the most prevalent human birth defects, congenital heart disease (CHD) affects roughly 0.8% of newborns (
Whole-genome sequencing (WGS) is becoming the method of choice for discovering de novo variants in CHD. Supporting the use of WGS for discovering molecular mechanisms underlying CHD, a recent study illustrated that the potential contribution from disruptive non-coding variants was at least as high as that from coding-variants (Richter et al., 2020). However, several factors complicate the functional annotation of disease-associated non-coding variants (Zhang and Lupski, 2015). In the case of common genetic variation associated with CHD-related phenotypes uncovered by GWAS, the tagged SNPs used will be in linkage disequilibrium (LD) with other SNPs that may represent the true causal variant. Even if a likely pathogenic non-coding mutation or copy number variation is nominated, one must then ascertain when and where this change impacts development and disease. In the following section, we briefly review insights into heart enhancer function revealed by human genetic studies.
Connecting Non-coding Variants to Cardiovascular Diseases
Only a handful of non-coding variants linked to cardiovascular diseases have been functionally dissected (Table 6). Compared to studying the function of a protein coding gene mutation, the functional characterization of non-coding disease associated variants is challenging. An early example of this was done for a genetic variant on human chromosome 9p21 harboring multiple SNPs associated with myocardial infarction and CAD (reviewed by Samani and Schunkert, 2008). A large 70 kb deletion of the whole orthologous sequence in the mouse genome severely reduced the expression of the nearby cardiac genes (Cdkn2a/b) and affected aortic smooth muscle cell proliferation and senescence. Allele-specific analysis of Cdkn2b transcripts in the heterozygous mice revealed a lack of cis-acting enhancers as the main mechanism underlying Cdkn2b downregulation, suggesting this genetic susceptibility interval contains enhancers that could be affected by the discovered sequence polymorphisms (Visel et al., 2010). However, disruption of cis-regulatory elements is not the only mechanism that contributes to diseases risk. Other studies revealed that expression of the long non-coding RNA (lncRNA) ANRII, which resides in chromosome 9q21, was affected by several SNPs within this region, and ANRII, in turn, could regulate other genes involved in vascular cell proliferation, adhesion, apoptosis, and remodeling (Holdt et al., 2010;
TABLE 6
| SNP | SNP position | Gene(s) | Disease | Evidence | References |
| SNPs within a 58 kb interval, include cis-regulatory elements | chr 9p21 | Cdkn2a/b | coronary artery disease | Deletion of the mouse orthologous interval severely impairs Cdkn2a/b expression nearby through a cis-acting mechanism. | Visel et al., 2010 |
| chr12:114704515: G>T, overlaps a TBX5 enhancer | 90 kb downstream of TBX5 | TBX5 | Septal defects | The risk allele ablates the cardiac enhancer activity | Smemo et al., 2012 |
| rs118026695:A>G and g.4574C>deletion | NKX2.5 promoter | NKX2.5 | ventricular septal defect | Risk alleles significantly upregulate the promoter activity | Pang et al., 2012 |
| g.17483564C>T and g.17483576C>G | NKX2.5 enhancer, 10 kb upstream | NKX2.5 | ventricular septal defect | Conserved with mouse AR1 Nkx2.5 enhancer, risk alleles significantly decrease the enhancer activity | Huang et al., 2013 |
| rs12190287:C>G rs12524865:C>A overlap enhancers | 3′ UTR of TCF21 | TCF21 | coronary heart disease | The protective alleles disrupts AP-1 binding and enhancer-associated histone modification, leading to TCF21 expression changes. | Miller et al., 2013 |
| rs12190287:C>G, overlaps a miRNA binding site | 3′ UTR of TCF21 | TCF21 | coronary heart disease | The protective allele (G) changes TCF21 transcript structure and disrupts miR-224 binding and post-transcriptional repression mediated by this miRNA. TGF-b and PDGF-bb signaling act upstream of miR-224 mediated allele-specific expression. | Miller et al., 2014 |
| rs6801957:G>A, overlaps an enhancer | Intron of SCN10A | SCN5A | cardiac rhythm disorder | The enhancer interacts with the SCN5A promoter. The minor allele disrupts a Tbox binding site and impairs the enhancer activity in the cardiac conduction system. | van den Boogaard et al., 2012, 2014 |
| rs7539120:A>T | An upstream enhancer of NOS1AP | NOS1AP | QT interval variations | The risk allele leads to increased enhancer activity. Overexpression of NOS1AP result in altered electrophysiology in cardiomyocytes | Kapoor et al., 2014 |
| rs4897612:G>T | −137 in VNN1 promoter | VNN1 | HDL cholesterol levels | eQTL of VNN1, allele-specific transcriptional activity, chromatin accessibility, binding of nuclear protein including SP-1, | Kaskow et al., 2014 |
| rs2050153:G>A | −587 in VNN1 promoter | VNN1 | HDL cholesterol levels | eQTL of VNN1, allele-specific chromatin accessibility, methylation and chromatin condensation | |
| rs138912749:T>C overlaps a miRNA binding site | 3′ UTR of SHOX2 | SHOX2 | atrial fibrillation | The minor allele creates a functional binding site for miR-92b-5p, which leads to reduced expression of SHOX2. | Hoffmann et al., 2016 |
| rs6489956:C>T overlaps two miRNA binding sites | 3′ UTR of TBX5 | TBX5 | CHD susceptibility | The minor allele shows increased binding to miR-9/30a, which leads to reduced expression of TBX5 | Wang et al., 2017 |
| rs7373779, rs41312411, rs11710077, rs13097780, rs6801957 | SCN5A-SCN10A GWAS locus | SCN5A | QT interval variations | Allele-specific enhancer activity and nuclear factor binding. (More putative variants were identified other than these five representative ones) | Kapoor et al., 2019 |
Functionally characterized non-coding SNPs implicated in cardiovascular disease.
Another well-studied example is rs12190287, a CAD-associated variant located within the 3′ UTR of the TCF21 gene. Two continuous studies together revealed a dual mechanism of this SNP in modulating TCF21 expression at both transcriptional and post-transcriptional levels (Miller et al., 2013, 2014). Overlapping a TCF21 enhancer, this variant causes dysregulation of TCF21 through allele-specific histone modifications (H3K4me1, H3K27ac, H3K27me1) and AP-1 factor (c-Jun, JunD, ATF3) binding. These allele-specific chromatin effects are further augmented upon PDGFR-β stimulation, which indicates that the vascular growth factor signaling also acts differently on this variant (Miller et al., 2013). Moreover, the same minor allele disrupts a miR-224 binding site within the 3′ UTR of TCF21, therefore, prevents the post-transcriptional repression of TCF21 mediated by this miRNA (Miller et al., 2014).
The ion channel genes SCN5A/SCN10A locus is another hotspot heavily loaded with variants linked to cardiac arrhythmia and conduction system disorders (Veerman et al., 2015). One cardiac arrhythmia-associated SNP rs6801957 is located within the intron of SCN10A but is encompassed by a human-mouse conserved enhancer that interacts with the nearby gene SCN5A (van den Boogaard et al., 2014). This variant, but not other variants in LD disrupts the binding of TBX3/TBX5 in vitro and reduces the activity of this enhancer in the cardiac conduct system (van den Boogaard et al., 2012). Overall, these variant-oriented studies revealed the molecular mechanisms through which single nucleotide substitutions could alter enhancer activity and lead to pathological gene expression.
Discovering Disruptive Non-coding Variants Near Cardiac Genes
The CREs controlling the expression of TFs (i.e., the regulators of the regulators) are prime candidate regions for discovering damaging mutations that lead to gene dosage-related phenotypes (van der Lee et al., 2020). Indeed, hypothesis driven dissection of enhancers near cardiac genes have revealed several examples of disease causing non-coding mutations that control haploinsufficient cardiac genes TBX5, NKX2.5, and SHOX2 (reviewed in
It had been known for over a decade that heterozygous mutations within TBX5 lead to Holt-Oram syndrome in humans (
In addition to enhancers and promoters, non-coding regulatory variation can impact miRNA binding sites, lncRNAs, or even several of these functional elements at the same time. In principle this could occur by disrupting or creating TF/miRNA binding sites, changing chromatin states, mediating different responses to extracellular signaling, or affecting lncRNA expression which in turn can affect gene regulation in trans (Table 6). For example a variant associated with increased CHD susceptibility was identified within the 3′ UTR of TBX5. This variant was shown to increase the binding of two miRNAs with the minor allele leading to a significant reduction in the expression of TBX5 through transcriptional and translational regulation (Wang et al., 2017). NKX2.5 mutations have also been implicated in diverse types of CHD, including ventricular septal defects (reviewed in
While there are relatively few hard-won examples of non-coding mutations that explain the molecular mechanism behind CHD, it is clear that a comprehensive annotation of heart enhancer location and function will accelerate molecular-based diagnoses and our understand of heart gene regulation.
Interpreting Non-coding Variants With Genome-Wide Enhancer Annotation
With the burst of cardiac epigenomic datasets in the past decade, the interpretation of heart disease-associated variants has developed from susceptible locus-centric to a genome-wide manner. Continuous efforts have been made to first establish a comprehensive enhancer annotation and then use for the fine-mapping non-coding variants (
With the promising future of functional genomics in non-coding variants dissection, generation and curation of transcriptome and epigenome datasets have been tailed toward studying a specific type of heart disease to achieve higher precision. For example, to understand causal variants for atrial fibrillation (AF), RNA-seq data and ATAC-seq specifically from the left atria were generated to identify potential CREs and target genes that were likely to be affected by the genetic variants within 104 AF-associated loci (van Ouwerkerk et al., 2019). Following this study, a functional enhancer screening of these AF-associated loci using STARR-seq found 24/55 the variant-containing enhancers with allele-specific activities, demonstrating the robustness of this approach. Deletion of the orthologous region of one such enhancer near Hcn4 in the mouse genome caused a loss of Hcn4 expression and cardiac defects (van Ouwerkerk et al., 2020).
In addition to our growing understanding of the regulatory logic underlying developmental gene expression, it is also important to acknowledge the contribution of pro-inflammatory processes on heart enhancer usage and gene expression. For instance, the rapid pro-inflammatory gene expression by the NF-κB transcription factor complex, which across cell types utilizes clusters of strong enhancers (also known as “super enhancers”) to rapidly deploy pro-inflammatory gene expression (
Integrating enhancer information into the functional annotation of non-coding variants is no doubt a powerful approach; however, it should be noted that disrupting enhancer activities is not the only mechanism underlying the pathological consequences of non-coding variants. Even with extensive efforts in curating heart enhancers, nearly 90% of the heart disease-associated LD SNPs did not overlap any heart enhancers in the compendium (
Emerging Techniques for the Functional Dissection of Heart Enhancers
So far, numerous putative heart enhancers have been identified in different conditions and cell types from several model organisms. However, compared to enhancer mapping, the throughput of current approaches for enhancer functional dissection, especially in vivo, remains a major bottleneck. Traditionally, each candidate enhancer is accessed individually via being placed upstream of a reporter gene and introduced into cells or in vivo organisms. Collective efforts using this approach have led to the establishment of central resources of validated enhancers, such as the Vista Enhancer Browser2 (Visel et al., 2007). To measure enhancer activity in a more high throughput manner, several methods have been developed through the years, such as massively parallel reporter assays (MPRA) (Melnikov et al., 2012; Patwardhan et al., 2012; Sharon et al., 2012), and self-transcribing active regulatory region sequencing (STARR-seq) (
Compared to all enhancer reporter assays, which introduces an atypical distance between candidate enhancers and the reporter genes, a complementary perhaps preferred way to understand enhancer functions is to dissect their activity and function in their endogenous loci. The ever-growing CRISPR-Cas9 toolbox provides many options for in situ enhancer dissection (reviewed in Klein et al., 2018; Pickar-Oliver and Gersbach, 2019; Xu and Qi, 2019). Individual enhancer deletions or substitutions have been routinely used to characterize enhancer functions in specific developmental processes (
Discussion, Concluding Remarks, and Future Perspectives
The past decade has witnessed an exponential growth of the numbers of putative heart enhancer regions identified, largely owing to rapid advances in epigenomic profiling approaches. These techniques are still growing at an ever-increasing speed and will undoubtedly continue to revolutionize the way that researchers annotate and interpret enhancer activities. Single-cell epigenomic techniques, especially the multi-omics approaches, will likely become one of the main driving forces in expanding the horizon of cardiac enhancers and regulatory networks in the next decade. However, it should be noted that many analytical challenges are inherently associated with single-cell epigenomic datasets that currently remain sparse and noisy (reviewed in Schwartzman and Tanay, 2015; Verma and Kumar, 2019). Robust computational and statistical models are needed to extract biological information from other irrelevant signals (e.g., technical noises, batch effect) and for integrating the multimodal data of different characteristics, dimensionalities, and coverages to model them in a single space. Methods addressing these challenges are rapidly emerging (reviewed in
In vivo functional characterization of enhancers, especially developmental enhancers, is still one of the biggest challenges lying ahead. As developmental genes are usually regulated by multiple enhancers with overlapping activities, it is reasonable to assume that most enhancers may have redundant functions in normal development (
On the other hand, we are in an era with unprecedented opportunities to overcome these challenges. The combined use of CRISPR technologies and single-cell genomics is likely to make a substantial contribution to functional enhancer dissections in the near future. With the concurrent advancement of these two technologies, it probably will not be too far until we can conduct mid- to large-scale in vivo enhancer screening. Moreover, coupling CRISPR with other single-cell epigenomic assays (e.g., single-cell accessibility chromatin) to target TFs or chromatin modifiers (Rubin et al., 2019; Sanjana et al., 2020), can provide information complementary to enhancer screens and together build toward a comprehensive regulatory network.
From traditional approaches to the newest genomic assays, the rich history of heart enhancer studies has not only left us with a wealth of knowledge about the genomic locations, functional roles, evolutionary conservation, and disease implications of heart enhancers but also opened up many challenges and unanswered questions. What are the best experimental designs and analytic strategies of single-cell epigenomic assays? How can we increase the scalability of functional enhancer assays and efficiently adopt them into in vivo contexts? Could we develop more robust and transferable computational methods that can not only predict heart enhancers but also determine their chamber-, cell-type or developmental-stage specific activities and how the activity of enhancers can be affected by non-coding variants? We may not be sure when these questions will be fully answered, but we can confidently anticipate that efforts made in tackling these challenges will push our understanding of heart enhancers and cardiac regulatory network to an unprecedented level.
Statements
Author contributions
XY researched, conceived the structure, created the figures and tables, and led the writing of the review. MW and IS developed the ideas and provided text for the review. All the authors read and edited the review.
Funding
This work was supported in part by The Hospital for Sick Children Restracomp Studentship and Connaught International Scholarship to XY and CIHR (FRN 156318 to MW and IS). MW was supported by the Canada Research Chairs Program and an Early Researcher Award from the Ontario Ministry of Research and Innovation.
Acknowledgments
We apologize to the authors whose work could not be covered or thoroughly discussed in this review due to space limitations. We would like to thank Mengyi Song, Huayun Hou, and Anna Prentice for reading the manuscript and providing feedback.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
AbudayyehO. O.GootenbergJ. S.EssletzbichlerP.HanS.JoungJ.BelantoJ. J.et al (2017). RNA targeting with CRISPR-Cas13.Nature550280–284.
2
AdamoR. F.GuayC. L.EdwardsA. V.WesselsA.BurchJ. B. E. (2004). GATA-6 gene enhancer contains nested regulatory modules for primary myocardium and the embedded nascent atrioventricular conduction system.Anat. Rec.280A1062–1071. 10.1002/ar.a.20105
3
AhmadS. M.BusserB. W.HuangD.CozartE. J.MichaudS.ZhuX.et al (2014). Machine learning classification of cell-specific cardiac enhancers uncovers developmental subnetworks regulating progenitor cell division and cell fate specification.Dev.141878–888. 10.1242/dev.101709
4
AkerbergB. N.GuF.VanDusenN. J.ZhangX.DongR.LiK.et al (2019). A reference map of murine cardiac transcription factor chromatin occupancy identifies dynamic and conserved enhancers.Nat. Commun.101–16.
5
AlexanianM.MaricD.JenkinsonS. P.MinaM.FriedmanC. E.TingC. C.et al (2017). A transcribed enhancer dictates mesendoderm specification in pluripotency.Nat. Commun.81–19.
6
Alvarez-DominguezJ. R.KnollM.GromatzkyA. A.LodishH. F. (2017). The super-enhancer-derived alncRNA-EC7/bloodlinc potentiates red blood cell development in trans.Cell Rep.192503–2514. 10.1016/j.celrep.2017.05.082
7
AndersonK. M.AndersonD. M.McAnallyJ. R.SheltonJ. M.Bassel-DubyR.OlsonE. N. (2016). Transcription of the non-coding RNA upperhand controls Hand2 expression and heart development.Nature21–13.
8
AnderssonR.GebhardC.Miguel-EscaladaI.HoofI.BornholdtJ.BoydM.et al (2014). An atlas of active enhancers across human cell types and tissues.Nature507455–461.
9
AngY.-S.RivasR. N.RibeiroA. J. S.SrivasR.RiveraJ.StoneN. R.et al (2016). Disease model of GATA4 mutation reveals transcription factor cooperativity in human cardiogenesis.Cell1671734.e22–1749.e22.
10
AngermuellerC.ClarkS. J.LeeH. J.MacaulayI. C.TengM. J.HuT. X.et al (2016). Parallel single-cell sequencing links transcriptional and epigenetic heterogeneity.Nat. Methods13229–232. 10.1038/nmeth.3728
11
AparicioS.MorrisonA.GouldA.GilthorpeJ.ChaudhuriC.RigbyP.et al (1995). Detecting conserved regulatory elements with the model genome of the Japanese puffer fish. Fugu rubripes.Proc. Natl. Acad. Sci. U.S.A.921684–1688. 10.1073/pnas.92.5.1684
12
ArkingD. E.PulitS. L.CrottiL.van der HarstP.MunroeP. B.KoopmannT. T.et al (2014). Genetic association study of QT interval highlights role for calcium signaling pathways in myocardial repolarization.Nat. Genet.46826–836.
13
ArnerE.DaubC. O.Vitting-SeerupK.AnderssonR.LiljeB.DrabløsF.et al (2015). Transcribed enhancers lead waves of coordinated transcription in transitioning mammalian cells.Science3471010–1014.
14
ArnoldC. D.GerlachD.SpiesD.MattsJ. A.SytnikovaY. A.PaganiM.et al (2014). Quantitative genome-wide enhancer activity maps for five Drosophila species show functional enhancer conservation and turnover during cis-regulatory evolution.Nat. Genet.46685–692. 10.1038/ng.3009
15
ArnoldC. D.GerlachD.StelzerC.BorynL. M.RathM.StarkA. (2013). Genome-wide quantitative enhancer activity maps identified by STARR-seq.Science3391074–1077. 10.1126/science.1232542
16
ArnoldP. R.WellsA. D.LiX. C. (2020). Diversity and emerging roles of enhancer RNA in regulation of gene expression and cell fate.Front. Cell Dev. Biol.7:377. 10.3389/fcell.2019.00377
17
ArnostiD. N.KulkarniM. M. (2005). Transcriptional enhancers: intelligent enhanceosomes or flexible billboards?J. Cell. Biochem.94890–898. 10.1002/jcb.20352
18
BallesterB.Medina-RiveraA.SchmidtD.Gonzàlez-PortaM.CarlucciM.ChenX.et al (2014). Multi-species, multi-transcription factor binding highlights conserved control of tissue-specific biological pathways.eLife31–29. 10.1515/bc.2003.001
19
BarnesR. M.HarrisI. S.JaehnigE. J.SaulsK.SinhaT.RojasA.et al (2016). MEF2C regulates outflow tract alignment and transcriptional control of Tdgf1.Development143774–779. 10.1242/dev.126383
20
BarnettP.PostmaA. V. (2015). Genetics of congenital heart disease: beyond half-measures.Trends Cardiovasc. Med.25302–304. 10.1016/j.tcm.2014.11.012
21
BarronM. E.BelaguliN. S.ShuX. Z.TrinhM.IyerD.MerloX.et al (2005). Serum response factor, an enriched cardiac mesoderm obligatory factor, is a downstream gene target for Tbx genes.J. Biol. Chem.28011816–11828. 10.1074/jbc.m412408200
22
BassonC. T.BachinskyD. R.LinR. C.LeviT.ElkinsJ. A.SoultsJ.et al (1997). Mutations in human cause limb and cardiac malformation in Holt-Oram syndrome.Nat. Genet.1530–35. 10.1038/ng0197-30
23
BassonC. T.HuangT.LinR. C.BachinskyD. R.WeremowiczS.VaglioA.et al (1999). Different TBX5 interactions in heart and limb defined by Holt-Oram syndrome mutations.Proc. Natl. Acad. Sci. U.S.A.962919–2924.
24
BejeranoG.PheasantM.MakuninI.StephenS.KentW. J.MattickJ. S.et al (2004). Ultraconserved elements in the human genome.Science3041321–1325. 10.1126/science.1098119
25
BerteroA.FieldsP. A.RamaniV.BonoraG.YardimciG. G.ReineckeH.et al (2019). Dynamics of genome reorganization during human cardiogenesis reveal an RBM20-dependent splicing factory.Nat. Commun.101–19.
26
BlackwoodE. M.KadonagaJ. T. (1998). Going the distance: a current view of enhancer action.Science28160–63. 10.1126/science.281.5373.60
27
BlowM. J.McCulleyD. J.LiZ.ZhangT.AkiyamaJ. A.HoltA.et al (2010). ChIP-Seq identification of weakly conserved heart enhancers.Nat. Genet.42806–810. 10.1038/ng.650
28
BogdanovicO.Fernandez-MiñánA.TenaJ. J.de la Calle-MustienesE.HidalgoC.van KruysbergenI.et al (2012). Dynamics of enhancer chromatin signatures mark the transition from pluripotency to cell specification during embryogenesis.Genome Res.222043–2053. 10.1101/gr.134833.111
29
BogdanovićO.SmitsA. H.de la Calle MustienesE.TenaJ. J.FordE.WilliamsR.et al (2016). Active DNA demethylation at enhancers during the vertebrate phylotypic period.Nat. Genet.48417–426. 10.1038/ng.3522
30
BonevB.Mendelson CohenN.SzaboQ.FritschL.PapadopoulosG. L.LublingY.et al (2017). Multiscale 3D genome rewiring during mouse neural development.Cell171557.e24–572.e24.
31
BonnS.ZinzenR. P.GirardotC.GustafsonE. H.Perez-GonzalezA.DelhommeN.et al (2012). Tissue-specific analysis of chromatin state identifies temporal signatures of enhancer activity during embryonic development.Nat. Genet.44148–156. 10.1038/ng.1064
32
BoogerdC. J.AneasI.SakabeN.DirschingerR. J.ChengQ. J.ZhouB.et al (2017). Probing chromatin landscape reveals roles of endocardial TBX20 in septation.J. Clin. Invest.1263023–3035. 10.1172/jci85350
33
BraaschI.GehrkeA. R.SmithJ. J.KawasakiK.ManousakiT.PasquierJ.et al (2016). The spotted gar genome illuminates vertebrate evolution and facilitates human-teleost comparisons.Nat. Genet.48427–437.
34
Brind’AmourJ.LiuS.HudsonM.ChenC.KarimiM. M.LorinczM. C. (2015). An ultra-low-input native ChIP-seq protocol for genome-wide profiling of rare cell populations.Nat. Commun.61–8.
35
BrownC. O.ChiX.Garcia-GrasE.ShiraiM.FengX. H.SchwartzR. J. (2004). The cardiac determination factor, Nkx2-5, is activated by mutual cofactors GATA-4 and Smad1/4 via a novel upstream enhancer.J. Biol. Chem.27910659–10669. 10.1074/jbc.m301648200
36
BrownJ. D.LinC. Y.DuanQ.GriffinG.FederationA. J.ParanalR. M.et al (2014). Nf-kb directs dynamic super enhancer formation in inflammation and atherogenesis.Mol. Cell56219–231. 10.1016/j.molcel.2014.08.024
37
BueckerC.WysockaJ. (2012). Enhancers as information integration hubs in development: lessons from genomics.Trends Genet.28276–284. 10.1016/j.tig.2012.02.008
38
BuenrostroJ. D.GiresiP. G.ZabaL. C.ChangH. Y.GreenleafW. J. (2013). Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position.Nat. Methods101213–1218. 10.1038/nmeth.2688
39
BuenrostroJ. D.WuB.LitzenburgerU. M.RuffD.GonzalesM. L.SnyderM. P.et al (2015). Single-cell chromatin accessibility reveals principles of regulatory variation.Nature523486–490. 10.1038/nature14590
40
BusserB. W.HaimovichJ.HuangD.OvcharenkoI.MichelsonA. M. (2015). Enhancer modeling uncovers transcriptional signatures of individual cardiac cell states in Drosophila.Nucleic Acids Res.431726–1739. 10.1093/nar/gkv011
41
CaloE.WysockaJ. (2013). Modification of enhancer chromatin: what, how, and why?Mol. Cell49825–837. 10.1016/j.molcel.2013.01.038
42
CannavòE.KhoueiryP.GarfieldD. A.GeeleherP.ZichnerT.GustafsonE. H.et al (2016). Shadow enhancers are pervasive features of developmental regulatory networks.Curr. Biol.2638–51. 10.1016/j.cub.2015.11.034
43
CaoJ.CusanovichD. A.RamaniV.AghamirzaieD.PlinerH. A.HillA. J.et al (2018). Joint profiling of chromatin accessibility and gene expression in thousands of single cells.Science3611380–1385. 10.1126/science.aau0730
44
CaputoL.WitzelH. R.KolovosP.CheedipudiS.LoosoM.MylonaA.et al (2015). The Isl1/Ldb1 complex orchestrates genome-wide chromatin organization to instruct differentiation of multipotent cardiac progenitors.Cell Stem Cell17287–299. 10.1016/j.stem.2015.08.007
45
Cardoso-MoreiraM.HalbertJ.VallotonD.VeltenB.ChenC.ShaoY.et al (2019). Gene expression across mammalian organ development.Nature571505–509.
46
CharitéJ.McFaddenD. G.MerloG.LeviG.ClouthierD. E.YanagisawaM.et al (2001). Role of Dlx6 in regulation of an endothelin-1-dependent, dHAND branchial arch enhancer.Genes Dev.153039–3049. 10.1101/gad.931701
47
ChatterjeeS.BourqueG.LufkinT. (2011). Conserved and non-conserved enhancers direct tissue specific transcription in ancient germ layer specific developmental control genes.BMC Dev. Biol.11:63. 10.1186/1471-213X-11-63
48
ChenS.LakeB. B.ZhangK. (2019). High-throughput sequencing of the transcriptome and chromatin accessibility in the same cell.Nat. Biotechnol.371452–1457. 10.1038/s41587-019-0290-0
49
ChenY.CaoX. (2009). NFAT directly regulates Nkx2-5 transcription during cardiac cell differentiation.Biol. Cell101335–350. 10.1042/bc20080108
50
ChiX.ChatterjeeP. K.WilsonW.ZhangS. X.DeMayoF. J.SchwartzR. J. (2005). Complex cardiac Nkx2-5 gene expression activated by noggin-sensitive enhancers followed by chamber-specific modules.Proc. Natl. Acad. Sci. U.S.A.10213490–13495. 10.1073/pnas.0504295102
51
ChoyM.-K.JavierreB. M.WilliamsS. G.BarossS. L.LiuY.WingettS. W.et al (2018). Promoter interactome of human embryonic stem cell-derived cardiomyocytes connects GWAS regions to cardiac gene networks.Nat. Commun.9:2526.
52
ChuT.RiceE. J.BoothG. T.SalamancaH. H.WangZ.CoreL. J.et al (2018). Chromatin run-on and sequencing maps the transcriptional regulatory landscape of glioblastoma multiforme.Nat. Genet.501553–1564. 10.1038/s41588-018-0244-3
53
ChungI.-M.RajakumarG. (2016). Genetics of congenital heart defects: the NKX2-5 Gene, a Key player.Genes7: 6. 10.3390/genes7020006
54
ChurkoJ. M.GargP.TreutleinB.VenkatasubramanianM.WuH.LeeJ.et al (2018). Defining human cardiac transcription factor hierarchies using integrated single-cell heterogeneity analysis.Nat. Commun.9:4906.
55
CirilloL. A.LinF. R.CuestaI.FriedmanD.JarnikM.ZaretK. S. (2002). Opening of compacted chromatin by early developmental transcription factors HNF3 (FoxA) and GATA-4.Mol. Cell9279–289. 10.1016/s1097-2765(02)00459-8
56
ClarkC. D.ZhangB.LeeB.EvansS. I.LassarA. B.LeeK. H. (2013). Evolutionary conservation of Nkx2.5 autoregulation in the second heart field.Dev. Biol.374198–209. 10.1016/j.ydbio.2012.11.007
57
ClarkS. J.ArgelaguetR.KapouraniC. A.StubbsT. M.LeeH. J.Alda-CatalinasC.et al (2018). ScNMT-seq enables joint profiling of chromatin accessibility DNA methylation and transcription in single cells e.Nat. Commun.91–9.
58
ClémentY.TorbeyP.Gilardi-HebenstreitP.CrolliusH. R. (2020). Enhancer-gene maps in the human and zebrafish genomes using evolutionary linkage conservation.Nucleic Acids Res.482357–2371. 10.1093/nar/gkz1199
59
CongrainsA.KamideK.KatsuyaT.YasudaO.OguroR.YamamotoK.et al (2012a). CVD-associated non-coding RNA, ANRIL, modulates expression of atherogenic pathways in VSMC.Biochem. Biophys. Res. Commun.419612–616. 10.1016/j.bbrc.2012.02.050
60
CongrainsA.KamideK.OguroR.YasudaO.MiyataK.YamamotoE.et al (2012b). Genetic variants at the 9p21 locus contribute to atherosclerosis through modulation of ANRIL and CDKN2A/B.Atherosclerosis220449–455. 10.1016/j.atherosclerosis.2011.11.017
61
CorcesM. R.TrevinoA. E.HamiltonE. G.GreensideP. G.Sinnott-ArmstrongN. A.VesunaS.et al (2017). An improved ATAC-seq protocol reduces background and enables interrogation of frozen tissues.Nat. Methods14959–962. 10.1038/nmeth.4396
62
CoreL. J.MartinsA. L.DankoC. G.WatersC. T.SiepelA.LisJ. T. (2014). Analysis of nascent RNA identifies a unified architecture of initiation regions at mammalian promoters and enhancers.Nat. Genet.461311–1320. 10.1038/ng.3142
63
CoreL. J.WaterfallJ. J.LisJ. T. (2008). Nascent RNA sequencing reveals widespread pausing and divergent initiation at human promoters.Science3221845–1848. 10.1126/science.1162228
64
CotneyJ.LengJ.YinJ.ReillyS. K.DemareL. E.EmeraD.et al (2013). The evolution of lineage-specific regulatory activities in the human embryonic limb.Cell154185–196. 10.1016/j.cell.2013.05.056
65
CreyghtonM. P.ChengA. W.WelsteadG. G.KooistraT.CareyB. W.SteineE. J.et al (2010). Histone H3K27ac separates active from poised enhancers and predicts developmental state.Proc. Natl. Acad. Sci. U.S A.10721931–21936. 10.1073/pnas.1016071107
66
CusanovichD. A.DazaR.AdeyA.PlinerH. A.ChristiansenL.GundersonK. L.et al (2015). Multiplex single-cell profiling of chromatin accessibility by combinatorial cellular indexing.Science348910–914. 10.1126/science.aab1601
67
CusanovichD. A.HillA. J.AghamirzaieD.DazaR. M.PlinerH. A.BerletchJ. B.et al (2018a). A single-cell atlas of in vivo mammalian chromatin accessibility.Cell1741309.e18–1324.e18.
68
CusanovichD. A.ReddingtonJ. P.GarfieldD. A.DazaR. M.AghamirzaieD.Marco-FerreresR.et al (2018b). The cis-regulatory dynamics of embryonic development at single-cell resolution.Nature555538–542. 10.1038/nature25981
69
DavisD. L.EdwardsA. V.JuraszekA. L.PhelpsA.WesselsA.BurchJ. B. E. (2001). A GATA-6 gene heart-region-specific enhancer provides a novel means to mark and probe a discrete component of the mouse cardiac conduction system.Mech. Dev.108105–119. 10.1016/s0925-4773(01)00500-7
70
DavisD. L.WesselsA.BurchJ. B. E. (2000). An Nkx-dependent enhancer regulates cGATA-6 gene expression during early stages of heart development.Dev. Biol.217310–322. 10.1006/dbio.1999.9561
71
De KoninckM.LapiE.Badía-CareagaC.CossíoI.Giménez-LlorenteD.Rodríguez-CorsinoM.et al (2020). Essential roles of cohesin STAG2 in Mouse embryonic development and adult tissue homeostasis.Cell Rep.32:108014. 10.1016/j.celrep.2020.108014
72
de la Calle-MustienesE.FeijóoC. G.ManzanaresM.TenaJ. J.Rodríguez-SeguelE.LetiziaA.et al (2005). A functional survey of the enhancer activity of conserved non-coding sequences from vertebrate Iroquois cluster gene deserts.Genome Res.151061–1072. 10.1101/gr.4004805
73
Delgado-OlguínP.HuangY.LiX.ChristodoulouD.SeidmanC. E.SeidmanJ. G.et al (2012). Epigenetic repression of cardiac progenitor gene expression by Ezh2 is required for postnatal cardiac homeostasis.Nat. Genet.44343–347. 10.1038/ng.1068
74
DenkerA.De LaatW. (2016). The second decade of 3C technologies: detailed insights into nuclear organization.Genes Dev.301357–1382. 10.1101/gad.281964.116
75
DeutschM. A.DopplerS. A.LiX.LahmH.SantamariaG.CudaG.et al (2018). Reactivation of the Nkx2.5 cardiac enhancer after myocardial infarction does not presage myogenesis.Cardiovasc. Res.1141098–1114. 10.1093/cvr/cvy069
76
DevineW. P.WytheJ. D.GeorgeM.Koshiba-TakeuchiK.BruneauB. G. (2014). Early patterning and specification of cardiac progenitors in gastrulating mesoderm.eLife3:e03848.
77
DiaoY.FangR.LiB.MengZ.YuJ.QiuY.et al (2017). A tiling-deletion-based genetic screen for cis-regulatory element identification in mammalian cells.Nat. Methods14629–635. 10.1038/nmeth.4264
78
DiasN.SteinC. A. (2002). Antisense oligonucleotides: basic concepts and mechanisms.Mol. Cancer Ther.1347–355.
79
DickelD. E.BarozziI.ZhuY.Fukuda-YuzawaY.OsterwalderM.MannionB. J.et al (2016). Genome-wide compendium and functional assessment of in vivo heart enhancers.Nat. Commun.7:12923.
80
DickelD. E.YpsilantiA. R.RubensteinJ. L. R.PennacchioL. A.CorrespondenceA. V.GovD. (2018). Ultraconserved enhancers are required for normal development.Cell172491–499. 10.1016/j.cell.2017.12.017
81
DixonJ. R.JungI.SelvarajS.ShenY.Antosiewicz-BourgetJ. E.LeeA. Y.et al (2015). Chromatin architecture reorganization during stem cell differentiation.Nature518331–336. 10.1038/nature14222
82
DixonJ. R.SelvarajS.YueF.KimA.LiY.ShenY.et al (2012). Topological domains in mammalian genomes identified by analysis of chromatin interactions.Nature485376–380. 10.1038/nature11082
83
DodouE.VerziM. P.AndersonJ. P.XuS.-M.BlackB. L. (2004). Mef2c is a direct transcriptional target of ISL1 and GATA factors in the anterior heart field during mouse embryonic development.Development1313931–3942. 10.1242/dev.01256
84
Domazet-LošoT.TautzD. (2010). A phylogenetically based transcriptome age index mirrors ontogenetic divergence patterns.Nature468815–819. 10.1038/nature09632
85
DomckeS.HillA. J.DazaR. M.CaoJ.O’DayD. R.PlinerH. A.et al (2020). A human cell atlas of fetal chromatin accessibility.Science370:eaba7612. 10.1126/science.aba7612
86
DopplerS. A.WernerA.BarzM.LahmH.DeutschM. A.DreßenM.et al (2014). Myeloid zinc finger 1 (Mzf1) differentially modulates murine cardiogenesis by interacting with an Nkx2.5 cardiac enhancer.PLoS One9:e113775. 10.1371/journal.pone.0113775
87
DupaysL.ShangC.WilsonR.KotechaS.WoodS.TowersN.et al (2015). Sequential binding of MEIS1 and NKX2-5 on the Popdc2 gene: a mechanism for spatiotemporal regulation of enhancers during cardiogenesis.Cell Rep.13183–195. 10.1016/j.celrep.2015.08.065
88
EppingaR. N.HagemeijerY.BurgessS.HindsD. A.StefanssonK.GudbjartssonD. F.et al (2016). Identification of genomic loci associated with resting heart rate and shared genetic predictors with all-cause mortality.Nat. Genet.481557–1563. 10.1038/ng.3708
89
EresI. E.GiladY. (2020). A TAD Skeptic: is 3D genome topology conserved?Trends Genet.S0168-9525, 30298–30305.
90
EresI. E.LuoK.HsiaoC. J.BlakeL. E.GiladY. (2019). Reorganization of 3D genome structure may contribute to gene regulatory evolution in primates.PLoS Genet.15:e1008278. 10.1371/journal.pgen.1008278
91
EspinosaJ. M. (2016). Revisiting lncRNAs: how do you know yours is not an eRNA?Mol. Cell621–2. 10.1016/j.molcel.2016.03.022
92
FahedA. C.GelbB. D.SeidmanJ. G.SeidmanC. E. (2013). Genetics of congenital heart disease: the glass half empty.Circ. Res.112707–720. 10.1161/circresaha.112.300853
93
FangR.YuM.LiG.CheeS.LiuT.SchmittA. D.et al (2016). Mapping of long-range chromatin interactions by proximity ligation-assisted ChIP-seq.Cell Res.261345–1348. 10.1038/cr.2016.137
94
FarleyE. K.OlsonK. M.ZhangW.BrandtA. J.RokhsarD. S.LevineM. S. (2015). Suboptimization of developmental enhancers.Science350325–328. 10.1126/science.aac6948
95
FarleyE. K.OlsonK. M.ZhangW.RokhsarD. S.LevineM. S. (2016). Syntax compensates for poor binding sites to encode tissue specificity of developmental enhancers.Proc. Natl. Acad. Sci. U.S.A.1136508–6513. 10.1073/pnas.1605085113
96
FieldA.AdelmanK. (2020). Evaluating enhancer function and transcription.Annu. Rev. Biochem.89213–234. 10.1146/annurev-biochem-011420-095916
97
FisherS.GriceE. A.VintonR. M.BesslingS. L.McCallionA. S. (2006). Conservation of RET regulatory function from human to zebrafish without sequence similarity.Science312276–279. 10.1126/science.1124070
98
FlavahanW. A.DrierY.LiauB. B.GillespieS. M.VenteicherA. S.Stemmer-RachamimovA. O.et al (2016). Insulator dysfunction and oncogene activation in IDH mutant gliomas.Nature529110–114. 10.1038/nature16490
99
ForcatoM.RomanoO.BicciatoS. (2020). Computational methods for the integrative analysis of single-cell data.Brief. Bioinform.20201–10.
100
FrankeM.IbrahimD. M.AndreyG.SchwarzerW.HeinrichV.SchöpflinR.et al (2016). Formation of new chromatin domains determines pathogenicity of genomic duplications.Nature538265–269. 10.1038/nature19800
101
FrankelN.DavisG. K.VargasD.WangS.PayreF.SternD. L. (2010). Phenotypic robustness conferred by apparently redundant transcriptional enhancers.Nature466490–493. 10.1038/nature09158
102
FriedliM.BardeI.ArcangeliM.VerpS.QuazzolaA.ZakanyJ.et al (2010). A systematic enhancer screen using lentivector transgenesis identifies conserved and non-conserved functional elements at the Olig1 and Olig2 locus.PLoS One5:e15741. 10.1371/journal.pone.0015741
103
FulcoC. P.NasserJ.JonesT. R.MunsonG.BergmanD. T.SubramanianV.et al (2019). Activity-by-contact model of enhancer–promoter regulation from thousands of CRISPR perturbations.Nat. Genet.511664–1669. 10.1038/s41588-019-0538-0
104
FullwoodM. J.LiuM. H.PanY. F.LiuJ.XuH.MohamedY. B.et al (2009). An oestrogen-receptor-α-bound human chromatin interactome.Nature46258–64.
105
FuquaT.JordanJ.Elize van BreugelM.HalavatyiA.TischerC.PolidoroP.et al (2020). Dense and pleiotropic regulatory information in a developmental enhancer.Nature587235–239. 10.1038/s41586-020-2816-5
106
GalangG.MandlaR.RuanH.JungC.SinhaT.StoneN. R.et al (2020). ATAC-seq reveals an Isl1 enhancer that regulates sinoatrial node development and function.Circ. Res.1271502–1518. 10.1161/circresaha.120.317145
107
GasperiniM.FindlayG. M.McKennaA.MilbankJ. H.LeeC.ZhangM. D.et al (2017). CRISPR/Cas9-mediated scanning for regulatory elements required for HPRT1 expression via thousands of large, programmed genomic deletions.Am. J. Hum. Genet.101192–205. 10.1016/j.ajhg.2017.06.010
108
GasperiniM.HillA. J.McFaline-FigueroaJ. L.MartinB.KimS.ZhangM. D.et al (2019). A genome-wide framework for mapping gene regulation via cellular genetic screens.Cell176377.e19–390.e19.
109
GhandiM.LeeD.Mohammad-NooriM.BeerM. A. (2014). Enhanced regulatory sequence prediction using gapped k-mer features.PLoS Comput. Biol.10:e1003711. 10.1371/journal.pcbi.1003711
110
GibbN.LazicS.YuanX.DeshwarA. R.LeslieM.WilsonM. D.et al (2018). Hey2 regulates the size of the cardiac progenitor pool during vertebrate heart development.Development145:dev167510. 10.1242/dev.167510
111
GilN.UlitskyI. (2020). Regulation of gene expression by cis-acting long non-coding RNAs.Nat. Rev. Genet.21102–117. 10.1038/s41576-019-0184-5
112
GilsbachR.SchwadererM.PreisslS.GrüningB. A.KranzhöferD.SchneiderP.et al (2018). Distinct epigenetic programs regulate cardiac myocyte development and disease in the human heart in vivo.Nat. Commun.9:391.
113
GoldmanJ. A.KuzuG.LeeN.KarasikJ.GemberlingM.FogliaM. J.et al (2017). Resolving heart regeneration by replacement histone profiling.Dev. Cell40392.e6–404.e6.
114
Gomez-VelazquezM.Badia-CareagaC.Lechuga-ViecoA. V.Nieto-ArellanoR.TenaJ. J.RollanI.et al (2017). CTCF counter-regulates cardiomyocyte development and maturation programs in the embryonic heart.PLoS Genet.13:e1006985. 10.1371/journal.pgen.1006985
115
GorkinD. U.BarozziI.ZhaoY.ZhangY.HuangH.LeeA. Y.et al (2020). An atlas of dynamic chromatin landscapes in mouse fetal development.Nature583744–751.
116
GroteP.WittlerL.HendrixD.KochF.WährischS.BeisawA.et al (2013). The tissue-specific lncRNA fendrr is an essential regulator of heart and body wall development in the mouse.Dev. Cell24206–214. 10.1016/j.devcel.2012.12.012
117
GrubertF.SrivasR.SpacekD. V.KasowskiM.Ruiz-VelascoM.Sinnott-ArmstrongN.et al (2020). Landscape of cohesin-mediated chromatin loops in the human genome.Nature583737–743. 10.1038/s41586-020-2151-x
118
GuoY.XuQ.CanzioD.ShouJ.LiJ.GorkinD. U.et al (2015). CRISPR inversion of CTCF sites alters genome topology and enhancer/promoter function.Cell162900–910. 10.1016/j.cell.2015.07.038
119
HanssenL. L. P.KassoufM. T.OudelaarA. M.BiggsD.PreeceC.DownesD. J.et al (2017). Tissue-specific CTCF-cohesin-mediated chromatin architecture delimits enhancer interactions and function in vivo.Nat. Cell Biol.19952–961. 10.1038/ncb3573
120
HaoY.HaoS.Andersen-NissenE.MauckW. M.IIIZhengS.ButlerA.et al (2020). Integrated analysis of multimodal single-cell data.bioRxiv [Preprint]. 10.1101/2020.10.12.335331
121
HareE. E.PetersonB. K.IyerV. N.MeierR.EisenM. B. (2008). Sepsid even-skipped enhancers are functionally conserved in Drosophila despite lack of sequence conservation.PLoS Genet.4:e1000106. 10.1371/journal.pgen.1000106
122
HarmstonN.Ing-SimmonsE.TanG.PerryM.MerkenschlagerM.LenhardB. (2017). Topologically associating domains are ancient features that coincide with Metazoan clusters of extreme noncoding conservation.Nat. Commun.8:441.
123
HashimotoH.WangZ.GarryG. A.MalladiV. S.BottenG. A.YeW.et al (2019). Cardiac reprogramming factors synergistically activate genome-wide cardiogenic stage-specific enhancers.Cell Stem Cell2569.e5–86.e5.
124
HeA.GuF.HuY.MaQ.YeL. Y.AkiyamaJ. A.et al (2014). Dynamic GATA4 enhancers shape the chromatin landscape central to heart development and disease.Nat. Commun.5:4907.
125
HeA.KongS. W.MaQ.PuW. T. (2011). Co-occupancy by multiple cardiac transcription factors identifies transcriptional enhancers active in heart.Proc. Natl. Acad. Sci. U.S.A.1085632–5637. 10.1073/pnas.1016959108
126
HeC. Z.BurchJ. B. E. (1997). The chicken GATA-6 locus contains multiple control regions that confer distinct patterns of heart region-specific expression in transgenic mouse embryos.J. Biol. Chem.27228550–28556. 10.1074/jbc.272.45.28550
127
Heicklen-KleinA.EvansT. (2004). T-box binding sites are required for activity of a cardiac GATA-4 enhancer.Dev. Biol.267490–504. 10.1016/j.ydbio.2003.09.042
128
HeinzS.RomanoskiC. E.BennerC.GlassC. K. (2015). The selection and function of cell type-specific enhancers.Nat. Rev. Mol. Cell Biol.16144–154. 10.1038/nrm3949
129
HenikoffS.HenikoffJ.Kaya-OkurH. S.AhmadK. (2020). Efficient chromatin accessibility mapping in situ by nucleosome-tethered tagmentation.eLife9:e63274. 10.7554/eLife.63274
130
HillerM.AgarwalS.NotwellJ. H.ParikhR.GuturuH.WengerA. M.et al (2013). Computational methods to detect conserved non-genic elements in phylogenetically isolated genomes: application to zebrafish.Nucleic Acids Res.41:e151. 10.1093/nar/gkt557
131
HoffmannS.ClaussS.BergerI. M.WeißB.MontalbanoA.RöthR.et al (2016). Coding and non-coding variants in the SHOX2 gene in patients with early-onset atrial fibrillation.Basic Res. Cardiol.1111–15.
132
HoldtL. M.BeutnerF.ScholzM.GielenS.GäbelG.BergertH.et al (2010). ANRIL expression is associated with atherosclerosis risk at chromosome 9p21.Arterioscler. Thromb. Vasc. Biol.30620–627.
133
HonkoopH.de BakkerD. E. M.AharonovA.KruseF.ShakkedA.NguyenP. D.et al (2019). Single-cell analysis uncovers that metabolic reprogramming by ErbB2 signaling is essential for cardiomyocyte proliferation in the regenerating heart.eLife81–27.
134
HsiehC. L.FeiT.ChenY.LiT.GaoY.WangX.et al (2014). Enhancer RNAs participate in androgen receptor-driven looping that selectively enhances gene activation.Proc. Natl. Acad. Sci. U.S.A.1117319–7324. 10.1073/pnas.1324151111
135
HuP.LiuJ.ZhaoJ.WilkinsB. J.LupinoK.WuH.et al (2018). Single-nucleus transcriptomic survey of cell diversity and functional maturation in postnatal mammalian hearts.Genes Dev.321344–1357. 10.1101/gad.316802.118
136
HuT.YamagishiH.MaedaJ.McAnallyJ.YamagishiC.SrivastavaD. (2004). Tbx1 regulates fibroblast growth factors in the anterior heart field through a reinforcing autoregulatory loop involving forkhead transcription factors.Development1315491–5502. 10.1242/dev.01399
137
HuangW.MengH.QiaoY.PangS.ChenD.YanB. (2013). Two novel and functional DNA sequence variants within an upstream enhancer of the human NKX2-5 gene in ventricular septal defects.Gene524152–155. 10.1016/j.gene.2013.04.043
138
IharaD.WatanabeY.SeyaD.AraiY.IsomotoY.NakanoA.et al (2020). Expression of Hey2 transcription factor in the early embryonic ventricles is controlled through a distal enhancer by Tbx20 and Gata transcription factors.Dev. Biol.461124–131. 10.1016/j.ydbio.2020.02.001
139
IkléJ. M.ArtingerK. B.ClouthierD. E. (2012). Identification and characterization of the zebrafish pharyngeal arch-specific enhancer for the basic helix-loop-helix transcription factor Hand2.Dev. Biol.368118–126. 10.1016/j.ydbio.2012.05.003
140
IrieN.KurataniS. (2011). Comparative transcriptome analysis reveals vertebrate phylotypic period during organogenesis.Nat. Commun.2:248.
141
IrieN.Sehara-FujisawaA. (2007). The vertebrate phylotypic stage and an early bilaterian-related stage in mouse embryogenesis defined by genomic information.BMC Biol.5:1. 10.1186/1741-7007-5-1
142
IrimiaM.TenaJ. J.AlexisM. S.Fernandez-MiñanA.MaesoI.BogdanovicO.et al (2012). Extensive conservation of ancient microsynteny across metazoans due to cis-regulatory constraints.Genome Res222356–2367. 10.1101/gr.139725.112
143
JavierreB. M.BurrenO. S.WilderS. P.KreuzhuberR.HillS. M.SewitzS.et al (2016). Lineage-specific genome architecture links enhancers and non-coding disease variants to target gene promoters.Cell1671369.e19–1384.e19.
144
JiaG.PreussnerJ.ChenX.GuentherS.YuanX.YekelchykM.et al (2018). Single cell RNA-seq and ATAC-seq analysis of cardiac progenitor cell transition states and lineage settlement.Nat. Commun.9:4877.
145
JinH.StojnicR.AdryanB.OzdemirA.StathopoulosA.FraschM. (2013). Genome-wide screens for in vivo tinman binding sites identify cardiac enhancers with diverse functional architectures.PLoS Genet.9:e1003195. 10.1371/journal.pgen.1003195
146
JinX.SimmonsS. K.GuoA.ShettyA. S.KoM.NguyenL.et al (2020). In vivo Perturb-Seq reveals neuronal and glial abnormalities associated with autism risk genes.Science370:eaaz6063. 10.1126/science.aaz6063
147
JohnsonD. S.DavidsonB.BrownC. D.SmithW. C.SidowA. (2004). Noncoding regulatory sequences of Ciona exhibit strong correspondence between evolutionary constraint and functional importance.Genome Res.142448–2456. 10.1101/gr.2964504
148
JungI.SchmittA.DiaoY.LeeA. J.LiuT.YangD.et al (2019). A compendium of promoter-centered long-range chromatin interactions in the human genome.Nat. Genet.511442–1449. 10.1038/s41588-019-0494-8
149
JunionG.SpivakovM.GirardotC.BraunM.GustafsonE. H.BirneyE.et al (2012). A transcription factor collective defines cardiac cell fate and reflects lineage history.Cell148473–486. 10.1016/j.cell.2012.01.030
150
KaikkonenM. U.SpannN. J.HeinzS.RomanoskiC. E.AllisonK. A.StenderJ. D.et al (2013). Remodeling of the enhancer landscape during macrophage activation is coupled to enhancer transcription.Mol. Cell51310–325. 10.1016/j.molcel.2013.07.010
151
KalinkaA. T.VargaK. M.GerrardD. T.PreibischS.CorcoranD. L.JarrellsJ.et al (2010). Gene expression divergence recapitulates the developmental hourglass model.Nature468811–816. 10.1038/nature09634
152
KapoorA.LeeD.ZhuL.SolimanE. Z.GroveM. L.BoerwinkleE.et al (2019). Multiple SCN5A variant enhancers modulate its cardiac gene expression and the QT interval.Proc. Natl. Acad. Sci. U.S.A.16610636–10645. 10.1073/pnas.1808734116
153
KapoorA.SekarR. B.HansenN. F.Fox-TalbotK.MorleyM.PihurV.et al (2014). An enhancer polymorphism at the cardiomyocyte intercalated disc protein NOS1AP locus is a major regulator of the QT interval.Am. J. Hum. Genet.94854–869. 10.1016/j.ajhg.2014.05.001
154
KaskowB. J.DiepeveenL. A.Michael ProffittJ.ReaA. J.UlgiatiD.BlangeroJ.et al (2014). Molecular prioritization strategies to identify functional genetic variants in the cardiovascular disease-associated expression QTL Vanin-1.Eur. J. Hum. Genet.22688–695. 10.1038/ejhg.2013.208
155
KawauchiS.CalofA. L.SantosR.Lopez-BurksM. E.YoungC. M.HoangM. P.et al (2009). Multiple organ system defects and transcriptional dysregulation in the Nipbl+/- Mouse, a model of cornelia de lange syndrome.PLoS Genet.5:e1000650. 10.1371/journal.pgen.1000650
156
Kaya-OkurH. S.WuS. J.CodomoC. A.PledgerE. S.BrysonT. D.HenikoffJ. G.et al (2019). CUT&Tag for efficient epigenomic profiling of small samples and single cells.Nat. Commun.10:1930.
157
KellyR. G. (2012). The Second Heart Field.Amsterdam: Elsevier Inc.
158
KhoueiryP.GirardotC.CiglarL.PengP. C.Hilary GustafsonE.SinhaS.et al (2017). Uncoupling evolutionary changes in DNA sequence, transcription factor occupancy and enhancer activity.eLife61–29.
159
KimT.-K.HembergM.GrayJ. M.CostaA. M.BearD. M.WuJ.et al (2010). Widespread transcription at neuronal activity-regulated enhancers.Nature465182–187. 10.1038/nature09033
160
KlannT. S.BlackJ. B.ChellappanM.SafiA.SongL.HiltonI. B.et al (2017). CRISPR-Cas9 epigenome editing enables high-throughput screening for functional regulatory elements in the human genome.Nat. Biotechnol.35561–568. 10.1038/nbt.3853
161
KlattenhoffC. A.ScheuermannJ. C.SurfaceL. E.BradleyR. K.FieldsP. A.SteinhauserM. L.et al (2013). Braveheart, a long noncoding RNA required for cardiovascular lineage commitment.Cell152570–583. 10.1016/j.cell.2013.01.003
162
KleinJ. C.ChenW.GasperiniM.ShendureJ. (2018). Identifying novel enhancer elements with CRISPR-Based screens.ACS Chem. Biol.13326–332. 10.1021/acschembio.7b00778
163
KochF.FenouilR.GutM.CauchyP.AlbertT. K.Zacarias-CabezaJ.et al (2011). Transcription initiation platforms and GTF recruitment at tissue-specific enhancers and promoters.Nat. Struct. Mol. Biol.18956–963. 10.1038/nsmb.2085
164
KorkmazG.LopesR.UgaldeA. P.NevedomskayaE.HanR.MyachevaK.et al (2016). Functional genetic screens for enhancer elements in the human genome using CRISPR-Cas9.Nat. Biotechnol.34192–198. 10.1038/nbt.3450
165
KrasnovA. N.MazinaM. Y.NikolenkoJ. V.VorobyevaN. E. (2016). On the way of revealing coactivator complexes cross-talk during transcriptional activation.Cell Biosci.6:15.
166
KunarsoG.ChiaN.-Y.JeyakaniJ.HwangC.LuX.ChanY.-S.et al (2010). Transposable elements have rewired the core regulatory network of human embryonic stem cells.Nat. Genet.42631–634. 10.1038/ng.600
167
KvonE. Z.KamnevaO. K.MeloU. S.BarozziI.OsterwalderM.MannionB. J.et al (2016). Progressive loss of function in a limb enhancer during snake evolution.Cell167633.e11–642.e11.
168
KvonE. Z.ZhuY.KelmanG.ViselA.DickelD. E.PennacchioL. A. (2020). Comprehensive in vivo interrogation reveals phenotypic impact of human enhancer variants.Cell1801262.e15–1271.e15.
169
KwakH.FudaN. J.CoreL. J.LisJ. T. (2013). Precise maps of RNA polymerase reveal how promoters direct initiation and pausing.Science339950–953. 10.1126/science.1229386
170
LaiF.OromU. A.CesaroniM.BeringerM.TaatjesD. J.BlobelG. A.et al (2013). Activating RNAs associate with Mediator to enhance chromatin architecture and transcription.Nature494497–501. 10.1038/nature11884
171
LambethL. S.SmithC. A. (2013). Short hairpin RNA-mediated gene silencing.Methods Mol. Biol.942205–232. 10.1007/978-1-62703-119-6_12
172
LaurentF.GirdziusaiteA.GamartJ.BarozziI.OsterwalderM.AkiyamaJ. A.et al (2017). HAND2 target gene regulatory networks control atrioventricular canal and cardiac valve development.Cell Rep.191602–1613. 10.1016/j.celrep.2017.05.004
173
LeeD.KapoorA.SafiA.SongL.HalushkaM. K.CrawfordG. E.et al (2018). Human cardiac cis-regulatory elements, their cognate transcription factors, and regulatory DNA sequence variants.Genome Res.281577–1588. 10.1101/gr.234633.118
174
LeeK. H.EvansS.RuanT. Y.LassarA. B. (2004). SMAD-mediated modulation of YY1 activity regulates the BMP response and cardiac-specific expression of a GATA4/5/6-dependent chick Nkx2.5 enhancer.Development1314709–4723. 10.1242/dev.01344
175
LescroartF.ChababS.LinX.RulandsS.PaulissenC.RodolosseA.et al (2014). Early lineage restriction in temporally distinct populations of Mesp1 progenitors during mammalian heart development.Nat. Cell Biol.16829–840. 10.1038/ncb3024
176
LetticeL. A.HeaneyS. J. H.PurdieL. A.LiL.de BeerP.OostraB. A.et al (2003). A long-range Shh enhancer regulates expression in the developing limb and fin and is associated with preaxial polydactyly.Hum. Mol. Genet.121725–1735. 10.1093/hmg/ddg180
177
LeungD.JungI.RajagopalN.SchmittA.SelvarajS.LeeA. Y.et al (2015). Integrative analysis of haplotype-resolved epigenomes across human tissues.Nature518350–354. 10.1038/nature14217
178
LiG.LiuY.ZhangY.KuboN.YuM.FangR.et al (2019). Joint profiling of DNA methylation and chromatin architecture in single cells.Nat. Methods16991–993. 10.1038/s41592-019-0502-z
179
LiK.LiuY.CaoH.ZhangY.GuZ.LiuX.et al (2020). Interrogation of enhancer function by enhancer-targeting CRISPR epigenetic editing.Nat. Commun.111–16.
180
LiN.WangZ. S.WangX. H.XuY. J.QiaoQ.LiX. M.et al (2018). A SHOX2 loss-of-function mutation underlying familial atrial fibrillation.Int. J. Med. Sci.151564–1572. 10.7150/ijms.27424
181
LiW.NotaniD.MaQ.TanasaB.NunezE.ChenA. Y.et al (2013). Functional roles of enhancer RNAs for oestrogen-dependent transcriptional activation.Nature498516–520. 10.1038/nature12210
182
LiW.NotaniD.RosenfeldM. G. (2016). Enhancers as non-coding RNA transcription units: recent insights and future perspectives.Nat. Rev. Genet.17207–223. 10.1038/nrg.2016.4
183
LiangM.SoomroA. U.TasneemS.AbattiL. E.AlizadaA.YuanX.et al (2020). Enhancer-gene rewiring in the pathogenesis of quebec platelet disorder.Blood1362679–2690.
184
LiberatoreC. M.Searcy-SchrickR. D.VincentE. B.YutzeyK. E. (2002). Nkx-2.5 gene induction in mice is mediated by a Smad consensus regulatory region.Dev. Biol.244243–256. 10.1006/dbio.2002.0604
185
Lieberman-AidenE.Van BerkumN. L.WilliamsL.ImakaevM.RagoczyT.TellingA.et al (2009). Comprehensive mapping of long-range interactions reveals folding principles of the human genome.Science326289–293. 10.1126/science.1181369
186
LienC. L.McAnallyJ.RichardsonJ. A.OlsonE. N. (2002). Cardiac-specific activity of an Nkx2-5 enhancer requires an evolutionarily conserved Smad binding site.Dev. Biol.244257–266. 10.1006/dbio.2002.0603
187
LienC. L.WuC.MercerB.WebbR.RichardsonJ. A.OlsonE. N. (1999). Control of early cardiac-specific transcription of Nkx2-5 by a GATA-dependent enhancer.Development12675–84.
188
LiuC.WangM.WeiX.WuL.XuJ.DaiX.et al (2019). An ATAC-seq atlas of chromatin accessibility in mouse tissues.Sci. Data6:65.
189
LiuJ.VialesR. R.KhoueiryP.ReddingtonJ. P.GirardotC.FurlongE. E. M.et al (2020). The hourglass model of evolutionary conservation during embryogenesis extends to developmental enhancers with signatures of positive selection.bioRxiv [Preprint]. 10.1101/2020.11.02.364505
190
LiuQ.JiangC.XuJ.ZhaoM. T.Van BortleK.ChengX.et al (2017). Genome-wide temporal profiling of transcriptome and open chromatin of early cardiomyocyte differentiation derived from hiPSCs and hESCs.Circ. Res.121376–391. 10.1161/circresaha.116.310456
191
LiuQ.Van BortleK.ZhangY.ZhaoM. T.ZhangJ. Z.GellerB. S.et al (2018). Disruption of mesoderm formation during cardiac differentiation due to developmental exposure to 13-cis-retinoic acid.Sci. Rep.81–11.
192
LohK. M.ChenA.KohP. W.DengT. Z.SinhaR.TsaiJ. M.et al (2016). Mapping the pairwise choices leading from pluripotency to human bone.Heart, and other mesoderm cell types.Cell166451–467. 10.1016/j.cell.2016.06.011
193
LongH. K.PrescottS. L.WysockaJ. (2016). Ever-changing landscapes: transcriptional enhancers in development and evolution.Cell1671170–1187. 10.1016/j.cell.2016.09.018
194
Luna-ZuritaL.StirnimannC. U.GlattS.KaynakB. L.ThomasS.BaudinF.et al (2016). Complex interdependence regulates heterotypic transcription factor distribution and coordinates cardiogenesis.Cell164999–1014. 10.1016/j.cell.2016.01.004
195
LupiáñezD. G.KraftK.HeinrichV.KrawitzP.BrancatiF.KlopockiE.et al (2015). Disruptions of topological chromatin domains cause pathogenic rewiring of gene-enhancer interactions.Cell1611012–1025. 10.1016/j.cell.2015.04.004
196
MacNeillC.FrenchR.EvansT.WesselsA.BurchJ. B. E. (2000). Modular regulation of cGATA-5 gene expression in the developing heart and gut.Dev. Biol.21762–76. 10.1006/dbio.1999.9539
197
MaedaJ.YamagishiH.McAnallyJ.YamagishiC.SrivastavaD. (2006). Tbx1 is regulated by forkhead proteins in the secondary heart field.Dev. Dyn.235701–710. 10.1002/dvdy.20686
198
MalikS.RoederR. G. (2010). The metazoan mediator co-activator complex as an integrative hub for transcriptional regulation.Nat. Rev. Genet.11761–772. 10.1038/nrg2901
199
MayD.BlowM. J.KaplanT.McCulleyD. J.JensenB. C.AkiyamaJ. A.et al (2012). Large-scale discovery of enhancers from human heart tissue.Nat. Genet.4489–93. 10.1038/ng.1006
200
McFaddenD. G.CharitéJ.RichardsonJ. A.SrivastavaD.FirulliA. B.OlsonE. N. (2000). A GATA-dependent right ventricular enhancer controls dHAND transcription in the developing heart.Development1275331–5341.
201
McPhersonC. E.ShimE. Y.FriedmanD. S.ZaretK. S. (1993). An active tissue-specific enhancer and bound transcription factors existing in a precisely positioned nucleosomal array.Cell75387–398. 10.1016/0092-8674(93)80079-t
202
MeersM. P.BrysonT. D.HenikoffJ. G.HenikoffS. (2019). Improved CUT&RUN chromatin profiling tools.eLife8:e46314.
203
MelnikovA.MuruganA.ZhangX.TesileanuT.WangL.RogovP.et al (2012). Systematic dissection and optimization of inducible enhancers in human cells using a massively parallel reporter assay.Nat. Biotechnol.30271–277. 10.1038/nbt.2137
204
MerkenschlagerM.NoraE. P. (2016). CTCF and cohesin in genome folding and transcriptional gene regulation.Annu. Rev. Genomics Hum. Genet.1717–43. 10.1146/annurev-genom-083115-022339
205
MeulemanW.MuratovA.RynesE.HalowJ.LeeK.BatesD.et al (2020). Index and biological spectrum of human DNase I hypersensitive sites.Nature584244–251. 10.1038/s41586-020-2559-3
206
MifsudB.Tavares-CadeteF.YoungA. N.SugarR.SchoenfelderS.FerreiraL.et al (2015). Mapping long-range promoter contacts in human cells with high-resolution capture Hi-C.Nat. Genet.47598–606. 10.1038/ng.3286
207
MikkelsenT. S.XuZ.ZhangX.WangL.GimbleJ. M.LanderE. S.et al (2010). Comparative epigenomic analysis of murine and human adipogenesis.Cell143156–169. 10.1016/j.cell.2010.09.006
208
MillerC. L.AndersonD. R.KunduR. K.RaiesdanaA.NürnbergS. T.DiazR.et al (2013). Disease-related growth factor and embryonic signaling pathways modulate an enhancer of TCF21 Expression at the 6q23.2 coronary heart disease locus.PLoS Genet.9:e1003652. 10.1371/journal.pgen.1003652
209
MillerC. L.HaasU.DiazR.LeeperN. J.KunduR. K.PatlollaB.et al (2014). Coronary heart disease-associated variation in TCF21 Disrupts a miR-224 binding site and miRNA-Mediated regulation.PLoS Genet.10:e1004263. 10.1371/journal.pgen.1004263
210
MiquerolL.KellyR. G. (2013). Organogenesis of the vertebrate heart.Wiley Interdiscip. Rev. Dev. Biol.217–29. 10.1002/wdev.68
211
MolkentinJ. D.AntosC.MercerB.TaigenT.MianoJ. M.OlsonE. N. (2000). Direct activation of a GATA6 cardiac enhancer by Nkx2.5: evidence for a reinforcing regulatory network of Nkx2.5 and GATA transcription factors in the developing heart.Dev. Biol.217301–309. 10.1006/dbio.1999.9544
212
MontefioriL. E.SobreiraD. R.SakabeN. J.AneasI.JoslinA. C.HansenG. T.et al (2018). A promoter interaction map for cardiovascular disease genetics.eLife7:e35788.
213
MoritaS.NoguchiH.HoriiT.NakabayashiK.KimuraM.OkamuraK.et al (2016). Targeted DNA demethylation in vivo using dCas9-peptide repeat and scFv-TET1 catalytic domain fusions.Nat. Biotechnol.341060–1065. 10.1038/nbt.3658
214
MoudgilA.WilkinsonM. N.ChenX.HeJ.CammackA. J.VasekM. J.et al (2020). Self-reporting transposons enable simultaneous readout of gene expression and transcription factor binding in single cells.Cell182992.e21–1008.e21.
215
MousaviK.ZareH.Dell’OrsoS.GrontvedL.Gutierrez-CruzG.DerfoulA.et al (2013). ERNAs promote transcription by establishing chromatin accessibility at defined genomic loci.Mol. Cell51606–617. 10.1016/j.molcel.2013.07.022
216
MozaffarianD.BenjaminE. J.GoA. S.ArnettD. K.BlahaM. J.CushmanM.et al (2015). Heart disease and stroke statistics—2015 update.Circulation131e29–e322.
217
MumbachM. R.RubinA. J.FlynnR. A.DaiC.KhavariP. A.GreenleafW. J.et al (2016). HiChIP: efficient and sensitive analysis of protein-directed genome architecture.Nat. Methods13919–922. 10.1038/nmeth.3999
218
MutoA.CalofA. L.LanderA. D.SchillingT. F. (2011). Multifactorial origins of heart and gut defects in nipbl-deficient zebrafish, a model of cornelia de lange syndrome.PLoS Biol.9:e1001181. 10.1371/journal.pbio.1001181
219
NarlikarL.SakabeN. J.BlanskiA. A. (2010). Genome-wide discovery of human heart enhancers.Genome Res.20381–392. 10.1101/gr.098657.109
220
Nature Methods. (2020). Method of the Year 2019: single-cell multimodal omics.Nat. Methods17:1. 10.1038/s41592-019-0703-5
221
NelsonC. P.GoelA.ButterworthA. S.KanoniS.WebbT. R.MarouliE.et al (2017). Association analyses based on false discovery rate implicate new loci for coronary artery disease.Nat. Genet.491385–1391.
222
Nicole RitterA.AliT.KopitchinskiN.DimmelerS.Grote CorrespondenceP. (2019). The lncRNA locus handsdown regulates cardiac gene programs and is essential for early mouse development.Dev. Cell50644–657. 10.1016/j.devcel.2019.07.013
223
NikpayM.GoelA.WonH.-H.HallL. M.WillenborgC.KanoniS.et al (2015). A comprehensive 1000 genomes–based genome-wide association meta-analysis of coronary artery disease.Nat. Genet.471121–1130. 10.1038/ng.3396
224
NobregaM. A.OvcharenkoI.AfzalV.RubinE. M. (2003). Scanning human gene deserts for long-range enhancers.Science302413–413. 10.1126/science.1088328
225
NordA. S.BlowM. J.AttanasioC.AkiyamaJ. A.HoltA.HosseiniR.et al (2013). Rapid and pervasive changes in genome-wide enhancer usage during mammalian development.Cell1551521–1531. 10.1016/j.cell.2013.11.033
226
NosedaM.PeterkinT.SimõesF. C.PatientR.SchneiderM. D. (2011). Cardiopoietic factors: extracellular signals for cardiac lineage commitment.Circ. Res.108129–152. 10.1161/circresaha.110.223792
227
OdomD. T.DowellR. D.JacobsenE. S.GordonW.DanfordT. W.MacIsaacK. D.et al (2007). Tissue-specific transcriptional regulation has diverged significantly between human and mouse.Nat. Genet.39730–732. 10.1038/ng2047
228
OlsonE. N. (2006). Gene regulatory networks in the evolution and development of the heart.Science3131922–1927. 10.1126/science.1132292
229
O’NeillL. P.VerMilyeaM. D.TurnerB. M. (2006). Epigenetic characterization of the early embryo with a chromatin immunoprecipitation protocol applicable to small cell populations.Nat. Genet.38835–841. 10.1038/ng1820
230
OsterwalderM.BarozziI.TissièresV.Fukuda-YuzawaY.MannionB. J.AfzalS. Y.et al (2018). Enhancer redundancy provides phenotypic robustness in mammalian development.Nature554239–243. 10.1038/nature25461
231
OsterwalderM.SpezialeD.ShoukryM.MohanR.IvanekR.KohlerM.et al (2014). HAND2 targets define a network of transcriptional regulators that compartmentalize the early limb bud mesenchyme.Dev. Cell31345–357. 10.1016/j.devcel.2014.09.018
232
OunzainS.MichelettiR.ArnanC.PlaisanceI.CecchiD.SchroenB.et al (2015). CARMEN, a human super enhancer-associated long noncoding RNA controlling cardiac specification, differentiation and homeostasis.J. Mol. Cell. Cardiol.8998–112. 10.1016/j.yjmcc.2015.09.016
233
OunzainS.PezzutoI.MichelettiR.BurdetF.ShetaR.NemirM.et al (2014). Functional importance of cardiac enhancer-associated noncoding RNAs in heart development and disease.Curr. Ther. Res. Clin. Exp.7655–70. 10.1016/j.yjmcc.2014.08.009
234
PaigeS. L.ThomasS.Stoick-CooperC. L.WangH.MavesL.SandstromR.et al (2012). A temporal chromatin signature in human embryonic stem cells identifies regulators of cardiac development.Cell151221–232. 10.1016/j.cell.2012.08.027
235
PaikD. T.ChoS.TianL.ChangH. Y.WuJ. C. (2020). Single-cell RNA sequencing in cardiovascular development, disease and medicine.Nat. Rev. Cardiol.17457–473. 10.1038/s41569-020-0359-y
236
PaneL. S.FulcoliF. G.CirinoA.AltomonteA.FerrentinoR.BilioM.et al (2018). Tbx1 represses Mef2c gene expression and is correlated with histone 3 deacetylation of the anterior heart field enhancer.DMM Dis. Model. Mech.11:dmm029967. 10.1242/dmm.029967
237
PangS.ShanJ.QiaoY.MaL.QinX.WanyanH.et al (2012). Genetic and functional analysis of the NKX2-5 gene promoter in patients with ventricular septal defects.Pediatr. Cardiol.331355–1361. 10.1007/s00246-012-0346-0
238
ParalkarV. R.TabordaC. C.HuangP.YaoY.KossenkovA. V.PrasadR.et al (2016). Unlinking an lncRNA from its associated cis element.Mol. Cell62104–110. 10.1016/j.molcel.2016.02.029
239
ParisM.KaplanT.LiX. Y.VillaltaJ. E.LottS. E.EisenM. B. (2013). Extensive divergence of transcription factor binding in Drosophila embryos with highly conserved gene expression.PLoS Genet.9:e1003748. 10.1371/journal.pgen.1003748
240
PatwardhanR. P.HiattJ. B.WittenD. M.KimM. J.SmithR. P.MayD.et al (2012). Massively parallel functional dissection of mammalian enhancers in vivo.Nat. Biotechnol.30265–270. 10.1038/nbt.2136
241
PawlakM.KedzierskaK. Z.MigdalM.NahiaK. A.RamilowskiJ. A.BugajskiL.et al (2019). Dynamics of cardiomyocyte transcriptome and chromatin landscape demarcates key events of heart development.Genome Res.29506–519. 10.1101/gr.244491.118
242
PennacchioL. A.AhituvN.MosesA. M.PrabhakarS.NobregaM. A.ShoukryM.et al (2006). In vivo enhancer analysis of human conserved non-coding sequences.Nature444499–502. 10.1038/nature05295
243
PerryM. W.BoettigerA. N.BothmaJ. P.LevineM. (2010). Shadow enhancers foster robustness of Drosophila gastrulation.Curr. Biol.201562–1567. 10.1016/j.cub.2010.07.043
244
Pickar-OliverA.GersbachC. A. (2019). The next generation of CRISPR–Cas technologies and applications.Nat. Rev. Mol. Cell Biol.20490–507. 10.1038/s41580-019-0131-5
245
Pijuan-SalaB.WilsonN. K.XiaJ.HouX.HannahR. L.KinstonS.et al (2020). Single-cell chromatin accessibility maps reveal regulatory programs driving early mouse organogenesis.Nat. Cell Biol.22487–497. 10.1038/s41556-020-0489-9
246
PoelmannR. E.Gittenberger-de GrootA. C. (2019). Development and evolution of the metazoan heart.Dev. Dyn.248634–656. 10.1002/dvdy.45
247
PostmaA. V.BezzinaC. R.ChristoffelsV. M. (2015). Genetics of congenital heart disease: the contribution of the noncoding regulatory genome.J. Hum. Genet.6113–19. 10.1038/jhg.2015.98
248
PottS. (2017). Simultaneous measurement of chromatin accessibility. DNA methylation, and nucleosome phasing in single cells.eLife6:e23203.
249
PugachevaE. M.KuboN.LoukinovD.TajmulM.KangS.KovalchukA. L.et al (2020). CTCF mediates chromatin looping via N-terminal domain-dependent cohesin retention.Proc. Natl. Acad. Sci. U.S.A.1172020–2031. 10.1073/pnas.1911708117
250
Quaife-RyanG. A.SimC. B.ZiemannM.KaspiA.RafehiH.RamialisonM.et al (2017). Multicellular transcriptional analysis of mammalian heart regeneration.Circulation1361123–1139. 10.1161/circulationaha.117.028252
251
QuinodozS. A.OllikainenN.TabakB.PallaA.SchmidtJ. M.DetmarE.et al (2018). Higher-Order inter-chromosomal hubs shape 3D genome organization in the nucleus.Cell174744.e24–757.e24.
252
RacedoS. E.HastenE.LinM.DevakanmalaiG. S.GuoT.OzbudakE. M.et al (2017). Reduced dosage of β-catenin provides significant rescue of cardiac outflow tract anomalies in a Tbx1 conditional null mouse model of 22q11.2 deletion syndrome.PLoS Genet.13:e1006687. 10.1371/journal.pgen.1006687
253
RacioppiC.WiecheckiK. A.ChristiaenL. (2019). Combinatorial chromatin dynamics foster accurate cardiopharyngeal fate choices.eLife8:e49921.
254
Rada-IglesiasA.BajpaiR.SwigutT.BrugmannS. A.FlynnR. A.WysockaJ. (2011). A unique chromatin signature uncovers early developmental enhancers in humans.Nature470279–283. 10.1038/nature09692
255
RaoS. S. P.HuntleyM. H.DurandN. C.StamenovaE. K.BochkovI. D.RobinsonJ. T.et al (2014). A 3D map of the human genome at kilobase resolution reveals principles of chromatin looping.Cell1591665–1680. 10.1016/j.cell.2014.11.021
256
ReecyJ. M.LiX.YamadaM.DeMayoF. J.NewmanC. S.HarveyR. P.et al (1999). Identification of upstream regulatory regions in the heart-expressed homeobox gene Nkx2-5.Development126839–849.
257
RichterF.MortonS. U.KimS. W.KitaygorodskyA.WassonL. K.ChenK. M.et al (2020). Genomic analyses implicate noncoding de novo variants in congenital heart disease.Nat. Genet.52769–777. 10.1038/s41588-020-0652-z
258
RojasA.De ValS.HeidtA. B.XuS. M.BristowJ.BlackB. L. (2005). Gata4 expression in lateral mesoderm is downstream of BMP4 and is activated directly by Forkhead and GATA transcription factors through a distal enhancer element.Development1323405–3417. 10.1242/dev.01913
259
RojasA.SchachterleW.XuS. M.BlackB. L. (2009). An endoderm-specific transcriptional enhancer from the mouse Gata4 gene requires GATA and homeodomain protein-binding sites for function in vivo.Dev. Dyn.2382588–2598. 10.1002/dvdy.22091
260
Rosa-GarridoM.ChapskiD. J.SchmittA. D.KimballT. H.KarbassiE.MonteE.et al (2017). High-resolution mapping of chromatin conformation in cardiac myocytes reveals structural remodeling of the epigenome in heart failure.Circulation1361613–1625. 10.1161/circulationaha.117.029430
261
RubinA. J.ParkerK. R.SatpathyA. T.QiY.WuB.OngA. J.et al (2019). Coupled single-Cell CRISPR screening and epigenomic profiling reveals causal gene regulatory networks.Cell176361.e17–376.e17.
262
SahlénP.AbdullayevI.RamsköldD.MatskovaL.RilakovicN.LötstedtB.et al (2015). Genome-wide mapping of promoter-anchored interactions with close to single-enhancer resolution.Genome Biol.16:156.
263
SamaniN. J.SchunkertH. (2008). Chromosome 9p21 and CARDIOVASCULAR DISEase.Circ. Cardiovasc. Genet.181–84. 10.1161/circgenetics.108.832527
264
SanjanaN.MontalbanoA.DengJ.MéndezMancillaA.WesselsH.-H.MossN. G.et al (2020). Scalable pooled CRISPR screens with single-cell chromatin accessibility profiling.bioRxiv [Preprint]. 10.1101/2020.11.20.390971
265
SantosR.KawauchiS.JacobsR. E.Lopez-BurksM. E.ChoiH.WikenheiserJ.et al (2016). Conditional creation and rescue of nipbl-deficiency in mice reveals multiple determinants of risk for congenital heart defects.PLoS Biol.14:e2000197. 10.1371/journal.pbio.2000197
266
SchachterleW.RojasA.XuS. M.BlackB. L. (2012). ETS-dependent regulation of a distal Gata4 cardiac enhancer.Dev. Biol.361439–449. 10.1016/j.ydbio.2011.10.023
267
SchaukowitchK.JooJ. Y.LiuX.WattsJ. K.MartinezC.KimT. K. (2014). Enhancer RNA facilitates NELF release from immediate early genes.Mol. Cell5629–42. 10.1016/j.molcel.2014.08.023
268
SchmidtD.SchwalieP. C.Ross-InnesC. S.HurtadoA.BrownG. D.CarrollJ. S.et al (2010a). A CTCF-independent role for cohesin in tissue-specific transcription.Genome Res.20578–588. 10.1101/gr.100479.109
269
SchmidtD.WilsonM. D.BallesterB.SchwalieP. C.BrownG. D.MarshallA.et al (2010b). Five-vertebrate ChIP-seq reveals the evolutionary dynamics of transcription factor binding.Science3281036–1040. 10.1126/science.1186176
270
SchmidtS. F.LarsenB. D.LoftA.MandrupS. (2016). Cofactor squelching: artifact or fact?BioEssays38618–626. 10.1002/bies.201600034
271
SchmidtS. F.LarsenB. D.LoftA.NielsenR.MadsenJ. G. S.MandrupS. (2015). Acute TNF-induced repression of cell identity genes is mediated by NFκB-directed redistribution of cofactors from super-enhancers.Genome Res.251281–1294. 10.1101/gr.188300.114
272
SchmittA. D.HuM.JungI.XuZ.QiuY.TanC. L.et al (2016). A compendium of chromatin contact maps reveals spatially active regions in the human genome.Cell Rep.172042–2059. 10.1016/j.celrep.2016.10.061
273
SchoenfelderS.Furlan-MagarilM.MifsudB.Tavares-CadeteF.SugarR.JavierreB. M.et al (2015). The pluripotent regulatory circuitry connecting promoters to their long-range interacting elements.Genome Res.25582–597. 10.1101/gr.185272.114
274
SchwartzmanO.TanayA. (2015). Single-cell epigenomics: techniques and emerging applications.Nat. Rev. Genet.16716–726. 10.1038/nrg3980
275
ScottI. C. (2012). Life Before Nkx2.5: Cardiovascular Progenitor Cells: Embryonic Origins and Development.Amsterdam: Elsevier Inc.
276
SearcyR. D.VincentE. B.LiberatoreC. M.YutzeyK. E. (1998). A GATA-dependent nkx-2.5 regulatory element activates early cardiac gene expression in transgenic mice.Development1254461–4470.
277
SerpooshanV.LiuY. H.BuikemaJ. W.GaldosF. X.ChirikianO.PaigeS.et al (2017). Nkx2.5+ cardiomyoblasts contribute to cardiomyogenesis in the neonatal heart.Sci. Rep.71–13.
278
SharonE.KalmaY.SharpA.Raveh-SadkaT.LevoM.ZeeviD.et al (2012). Inferring gene regulatory logic from high-throughput measurements of thousands of systematically designed promoters.Nat. Biotechnol.30521–530. 10.1038/nbt.2205
279
ShiiL.SongL.MaurerK.ZhangZ.SullivanK. E. (2017). SERPINB2 is regulated by dynamic interactions with pause-release proteins and enhancer RNAs.Mol. Immunol.8820–31. 10.1016/j.molimm.2017.05.005
280
ShinJ. T.PriestJ. R.OvcharenkoI.RoncoA.MooreR. K.BurnsC. G.et al (2005). Human-zebrafish non-coding conserved elements act in vivo to regulate transcription.Nucleic Acids Res.335437–5445. 10.1093/nar/gki853
281
SiggersT.DuyzendM. H.ReddyJ.KhanS.BulykM. L. (2011). Non-DNA-binding cofactors enhance DNA-binding specificity of a transcriptional regulatory complex.Mol. Syst. Biol.7:555. 10.1038/msb.2011.89
282
SimeonovD. R.GowenB. G.BoontanrartM.RothT. L.GagnonJ. D.MumbachM. R.et al (2017). Discovery of stimulation-responsive immune enhancers with CRISPR activation.Nature549111–115.
283
SimonisM.KlousP.SplinterE.MoshkinY.WillemsenR.de WitE.et al (2006). Nuclear organization of active and inactive chromatin domains uncovered by chromosome conformation capture–on-chip (4C).Nat. Genet.381348–1354. 10.1038/ng1896
284
SkeneP. J.HenikoffS. (2017). An efficient targeted nuclease strategy for high-resolution mapping of DNA binding sites.eLife61–35.
285
SlatteryM.RileyT.LiuP.AbeN.Gomez-AlcalaP.DrorI.et al (2011). Cofactor binding evokes latent differences in DNA binding specificity between hox proteins.Cell1471270–1282. 10.1016/j.cell.2011.10.053
286
SmemoS.CamposL. C.MoskowitzI. P.KriegerJ. E.PereiraA. C.NobregaM. A. (2012). Regulatory variation in a TBX5 enhancer leads to isolated congenital heart disease.Hum. Mol. Genet.213255–3263. 10.1093/hmg/dds165
287
SönmezerC.KleinendorstR.ImanciD.BarzaghiG.VillacortaL.SchübelerD.et al (2020). Molecular Co-occupancy identifies transcription factor binding cooperativity in vivo.Mol. Cell811–13. 10.1016/s0022-2836(02)00894-x
288
SpitzF.FurlongE. E. M. (2012). Transcription factors: from enhancer binding to developmental control.Nat. Rev. Genet.13613–626. 10.1038/nrg3207
289
SpurrellC. H.BarozziI.MannionB. J.BlowM. J.Fukuda-YuzawaY.AfzalS. Y.et al (2019). Genome-wide fetalization of enhancer architecture in heart disease.bioRxiv [Preprint]. 10.1101/591362
290
SteimleJ. D.MoskowitzI. P. (2017). TBX5: a key regulator of heart development.Curr. Top. Dev. Biol.122195–221.
291
StephensonA.AdamsJ. W.VaccarezzaM. (2017). The vertebrate heart: an evolutionary perspective.J. Anat.231787–797. 10.1111/joa.12687
292
TagleD. A.KoopB. F.GoodmanM.SlightomJ. L.HessD. L.JonesR. T. (1988). Embryonic ε and γ globin genes of a prosimian primate (Galago crassicaudatus). Nucleotide and amino acid sequences, developmental regulation and phylogenetic footprints.J. Mol. Biol.203439–455. 10.1016/0022-2836(88)90011-3
293
TakeuchiJ. K.MileikovskaiaM.Koshiba-TakeuchiK.HeidtA. B.MoriA. D.ArrudaE. P.et al (2005). Tbx20 dose-dependently regulates transcription factor networks required for mouse heart and motoneuron development.Development1322463–2474. 10.1242/dev.01827
294
TanakaM.ChenZ.BartunkovaS.YamasakiN.IzumoS. (1999). The cardiac homeobox gene Csx/Nkx2.5 lies genetically upstream of multiple genes essential for heart development.Development1261269–1280.
295
ThurmanR. E.RynesE.HumbertR.VierstraJ.MauranoM. T.HaugenE.et al (2012). The accessible chromatin landscape of the human genome.Nature48975–82.
296
TolkinT.ChristiaenL. (2012). Development and Evolution of the Ascidian Cardiogenic Mesoderm.Amsterdam: Elsevier Inc.
297
TorosinN. S.AnandA.GollaT. R.CaoW.EllisonC. E. (2020). 3D genome evolution and reorganization in the Drosophila melanogaster species group.PLoS Genet.16:e1009229. 10.1371/journal.pgen.1009229
298
TuckerN. R.ChaffinM.FlemingS. J.HallA. W.ParsonsV. A.BediK. C.et al (2020). Transcriptional and cellular diversity of the human heart.Circulation142466–482.
299
TurtonN.SwanR.MahenthiralingamT.PittsD.DykesI. M. (2019). The functions of long non-coding RNA during embryonic cardiovascular development and its potential for diagnosis and treatment of congenital heart disease.J. Cardiovasc. Dev. Dis.6:21. 10.3390/jcdd6020021
300
van den BoogaardM.SmemoS.Burnicka-TurekO.ArnoldsD. E.van de WerkenH. J. G.KlousP.et al (2014). A common genetic variant within SCN10A modulates cardiac SCN5A expression.J. Clin. Invest.1241844–1852. 10.1172/jci73140
301
van den BoogaardM.WongL. Y. E.TessadoriF.BakkerM. L.DreizehnterL. K.Wakkeret al (2012). Genetic variation in T-box binding element functionally affects SCN5A / SCN10A enhancer Find the latest version.J. Clin. Invest.1222519–2530. 10.1172/jci62613
302
van der LeeR.CorreardS.WassermanW. W. (2020). Deregulated regulators: disease-causing cis variants in transcription factor genes.Trends Genet.36523–539. 10.1016/j.tig.2020.04.006
303
van EifV. W.ProtzeS.BosadaF. M.YuanX.SinhaT.van DuijvenbodenK.et al (2020). Genome-wide analysis identifies an essential human tbx3 pacemaker enhancer.Circ. Res.1271522–1535. 10.1161/circresaha.120.317054
304
van OuwerkerkA. F.BosadaF.LiuJ.ZhangJ.van DuijvenbodenK.ChaffinM.et al (2020). Identification of functional variant enhancers associated with atrial fibrillation.Circ. Res.127229–243. 10.1161/circresaha.119.316006
305
van OuwerkerkA. F.BosadaF. M.van DuijvenbodenK.HillM. C.MontefioriL. E.ScholmanK. T.et al (2019). Identification of atrial fibrillation associated genes and functional non-coding variants.Nat. Commun.101–14.
306
VanoudenhoveJ.YankeeT. N.WildermanA.CotneyJ. (2020). Epigenomic and transcriptomic dynamics during human heart organogenesis.Circ. Res.127E184–E209.
307
VeermanC. C.WildeA. A. M.LodderE. M. (2015). The cardiac sodium channel gene SCN5A and its gene product NaV1.5: role in physiology and pathophysiology.Gene573177–187. 10.1016/j.gene.2015.08.062
308
VermaM.KumarV. (2019). Single-Cell Epigenomics: Technology and Applications.Amsterdam: Elsevier Inc.
309
VerziM. P.McCulleyD. J.De ValS.DodouE.BlackB. L. (2005). The right ventricle, outflow tract, and ventricular septum comprise a restricted expression domain within the secondary/anterior heart field.Dev. Biol.287134–145. 10.1016/j.ydbio.2005.08.041
310
VierstraJ.LazarJ.SandstromR.HalowJ.LeeK.BatesD.et al (2020). Global reference mapping of human transcription factor footprints.Nature583729–736. 10.1038/s41586-020-2528-x
311
VierstraJ.RynesE.SandstromR.ZhangM.CanfieldT.HansenR. S.et al (2014). Mouse regulatory DNA landscapes reveal global principles of cis-regulatory evolution.Science3461007–1012. 10.1126/science.1246426
312
Vietri RudanM.BarringtonC.HendersonS.ErnstC.OdomD. T.TanayA.et al (2015). Comparative Hi-C reveals that CTCF underlies evolution of chromosomal domain architecture.Cell Rep.101297–1309. 10.1016/j.celrep.2015.02.004
313
VillarD.BerthelotC.AldridgeS.RaynerT. F.LukkM.PignatelliM.et al (2015). Enhancer evolution across 20 mammalian species.Cell160554–566. 10.1016/j.cell.2015.01.006
314
ViselA.MinovitskyS.DubchakI.PennacchioL. A. (2007). VISTA Enhancer Browser–a database of tissue-specific human enhancers.Nucleic Acids Res.35D88–D92.
315
ViselA.TaherL.GirgisH.MayD.GolonzhkaO.HochR. V.et al (2013). A high-resolution enhancer atlas of the developing telencephalon.Cell152895–908. 10.1016/j.cell.2012.12.041
316
ViselA.ZhuY.MayD.AfzalV.GongE.AttanasioC.et al (2010). Targeted deletion of the 9p21 non-coding coronary artery disease risk interval in mice.Nature464409–412. 10.1038/nature08801
317
WaardenbergA. J.RamialisonM.BouvereR.HarveyR. P. (2014). Genetic networks governing heart development.Cold Spring Harb. Perspect. Med.41–24. 10.1155/2017/4135956
318
WamstadJ. A.AlexanderJ. M.TrutyR. M.ShrikumarA.LiF.EilertsonK. E.et al (2012). Dynamic and coordinated epigenetic regulation of developmental transitions in the cardiac lineage.Cell151206–220. 10.1016/j.cell.2012.07.035
319
WangF.LiuD.ZhangR.-R.YuL.-W.ZhaoJ.-Y.YangX.-Y.et al (2017). A TBX5 3′UTR variant increases the risk of congenital heart disease in the Han Chinese population.Cell Discov.31–13. 10.1161/circulationaha.111.circulationaha.111.050245
320
WangZ.CuiM.ShahA. M.TanW.LiuN.Bassel-DubyR.et al (2020). Cell-type-specific gene regulatory networks underlying murine neonatal heart regeneration at single-cell resolution.CellReports33:108472. 10.1016/j.celrep.2020.108472
321
WangD. Z.ValdezM. R.McAnallyJ.RichardsonJ.OlsonE. N.Da-ZhiW. (2001). Myogenic bHLH and MEF2 Proteins Directly Regulate the Mef2c gene - 4623.Full.pdf. Development. Available online at: https://dev.biologists.org/content/128/22/4623.short
322
WatanabeY.ZaffranS.KuroiwaA.HiguchiH.OguraT.HarveyR. P.et al (2012). Fibroblast growth factor 10 gene regulation in the second heart field by Tbx1, Nkx2-5, and Islet1 reveals a genetic switch for down-regulation in the myocardium.Proc. Natl. Acad. Sci. U.S.A.10918273–18280. 10.1073/pnas.1215360109
323
WissinkE. M.VihervaaraA.TippensN. D.LisJ. T. (2019). Nascent RNA analyses: tracking transcription and its regulation.Nat. Rev. Genet.20705–723. 10.1038/s41576-019-0159-6
324
WongE. S.ZhengD.TanS. Z.BowerN. L.GarsideV.VanwalleghemG.et al (2020). Deep conservation of the enhancer regulatory code in animals.Science370:eaax8137. 10.1126/science.aax8137
325
WoolfeA.GoodsonM.GoodeD. K.SnellP.McEwenG. K.VavouriT.et al (2005). Highly conserved non-coding sequences are associated with vertebrate development.PLoS Biol.3:e7. 10.1371/journal.pbio.0030007
326
XuX.QiL. S. (2019). A CRISPR–dCas toolbox for genetic engineering and synthetic biology.J. Mol. Biol.43134–47. 10.1016/j.jmb.2018.06.037
327
YanaiI.PeshkinL.JorgensenP.KirschnerM. W. (2011). Mapping gene expression in two Xenopus species: evolutionary constraints and developmental flexibility.Dev. Cell20483–496. 10.1016/j.devcel.2011.03.015
328
YangX. H.NadadurR. D.HilveringC. R.BianchiV.WernerM.MazurekS. R.et al (2017). Transcription-factor-dependent enhancer transcription defines a gene regulatory network for cardiac rhythm.eLife6:e31683.
329
YaoY.MinorP. J.ZhaoY.-T.JeongY.PaniA. M.KingA. N.et al (2016). Cis-regulatory architecture of a brain signaling center predates the origin of chordates.Nat. Genet.48575–580. 10.1038/ng.3542
330
YuanX.SongM.DevineP.BruneauB. G.ScottI. C.WilsonM. D. (2018). Heart enhancers with deeply conserved regulatory activity are established early in zebrafish development.Nat. Commun.9:4977.
331
ZaretK. S. (2020). Pioneer transcription factors initiating gene network changes.Annu. Rev. Genet.54367–385. 10.1146/annurev-genet-030220-015007
332
ZeitlingerJ. (2020). Seven myths of how transcription factors read the cis-regulatory code.Curr. Opin. Syst. Biol.2322–31. 10.1016/j.coisb.2020.08.002
333
ZentnerG. E.TesarP. J.ScacheriP. C. (2011). Epigenetic signatures distinguish multiple classes of enhancers with distinct cellular functions.Genome Res.211273–1283. 10.1101/gr.122382.111
334
ZhangF.LupskiJ. R. (2015). Non-coding genetic variants in human disease.Hum. Mol. Genet.24R102–R110.
335
ZhangY.LiT.PreisslS.AmaralM. L.GrinsteinJ. D.FarahE. N.et al (2019). Transcriptionally active HERV-H retrotransposons demarcate topologically associating domains in human pluripotent stem cells.Nat. Genet.511380–1388. 10.1038/s41588-019-0479-7
336
ZhouH.LiuJ.ZhouC.GaoN.RaoZ.LiH.et al (2018). In vivo simultaneous transcriptional activation of multiple genes in the brain using CRISPR-dCas9-activator transgenic mice.Nat. Neurosci.21440–446. 10.1038/s41593-017-0060-6
337
ZhouP.GuF.ZhangL.AkerbergB. N.MaQ.LiK.et al (2017). Mapping cell type-specific transcriptional enhancers using high affinity, lineage-specific Ep300 bioChIP-seq.eLife6:e22039.
338
ZinzenR. P.GirardotC.GagneurJ.BraunM.FurlongE. E. M. (2009). Combinatorial binding predicts spatio-temporal cis-regulatory activity.Nature46265–70. 10.1038/nature08531
Summary
Keywords
gene regulation, cardiac gene expression, transcription factor (TF), epigenomics and epigenetics, comparative genomics, enhancer
Citation
Yuan X, Scott IC and Wilson MD (2021) Heart Enhancers: Development and Disease Control at a Distance. Front. Genet. 12:642975. doi: 10.3389/fgene.2021.642975
Received
17 December 2020
Accepted
29 January 2021
Published
10 March 2021
Volume
12 - 2021
Edited by
Mayra Furlan-Magaril, National Autonomous University of Mexico, Mexico
Reviewed by
Mikhail Spivakov, Babraham Institute (BBSRC), United Kingdom; Koen Prange, University of Amsterdam, Netherlands
Updates

Check for updates
Copyright
© 2021 Yuan, Scott and Wilson.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Xuefei Yuan, xuefei.yuan@uni-heidelberg.deIan C. Scott, ian.scott@sickkids.caMichael D. Wilson, michaelwilson@sickkids.ca
†Present address: Xuefei Yuan, Center for Molecular Biology, Heidelberg University (ZMBH), Heidelberg, Germany
This article was submitted to Epigenomics and Epigenetics, a section of the journal Frontiers in Genetics
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.